[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15046
1. Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, Klambauer G, Landesmann B, Luijten M, MacKay C, Maxwell G, Meek ME, Paini A, Perkins E, Sobanski T, Villeneuve D, Waters KM, Whelan M: How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology. Toxicol Sci; 2017 Feb;155(2):326-336

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts are underway to transform regulatory toxicology and chemical safety assessment from a largely empirical science based on direct observation of apical toxicity outcomes in whole organism toxicity tests to a predictive one in which outcomes and risk are inferred from accumulated mechanistic understanding.
  • We argue that the systematic organization of knowledge into AOP frameworks can inform and help direct the design and development of computational prediction models that can further enhance the utility of mechanistic and in silico data for chemical safety assessment.
  • Examples of AOP-informed model development and its application to the assessment of chemicals for skin sensitization and multiple modes of endocrine disruption are provided.
  • The role of problem formulation, not only as a critical phase of risk assessment, but also as guide for both AOP and complementary model development is described.
  • The contents serve as a vision for how AOPs can be leveraged to facilitate development of computational prediction models needed to support the next generation of chemical safety assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology.
  • [Cites] Toxicol Sci. 2013 Mar;132(1):75-86 [23288054.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1333-47 [25824844.001]
  • [Cites] Environ Toxicol Chem. 2015 Jul;34(7):1623-33 [25943079.001]
  • [Cites] Toxicology. 2012 Jan 27;291(1-3):18-24 [22120538.001]
  • [Cites] Environ Toxicol Chem. 2010 Mar;29(3):730-41 [20821501.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1875-87 [26360911.001]
  • [Cites] PLoS One. 2013 May 30;8(5):e63308 [23737943.001]
  • [Cites] Environ Health Perspect. 2016 May;124(5):556-62 [26431337.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138 [20574894.001]
  • [Cites] Bioinformatics. 2012 May 1;28(9):1193-201 [22423044.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Toxicol Sci. 2015 Feb;143(2):319-32 [25338925.001]
  • [Cites] Environ Health Perspect. 2013 Sep;121(9):1002-10 [23771518.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2016 May-Jun;183-184:36-45 [26875912.001]
  • [Cites] Regul Toxicol Pharmacol. 2010 Dec;58(3):369-81 [20801182.001]
  • [Cites] Ann N Y Acad Sci. 2007 Dec;1115:1-22 [17925349.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Toxicol Sci. 2013 Jun;133(2):234-47 [23475784.001]
  • [Cites] Environ Res. 2012 Aug;117:90-9 [22770859.001]
  • [Cites] Environ Toxicol Chem. 2011 Feb;30(2):265-73 [21072840.001]
  • [Cites] BMC Syst Biol. 2011 May 05;5:63 [21545743.001]
  • [Cites] Int J Androl. 2008 Apr;31(2):209-23 [18217984.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):230-40 [19010444.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):14-25 [26500288.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Toxicol In Vitro. 2014 Feb;28(1):8-12 [24184331.001]
  • [Cites] Environ Sci Technol. 2016 May 3;50(9):4579-86 [26759916.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):471-83 [25236459.001]
  • [Cites] Environ Sci Technol. 2015 Jul 21;49(14):8804-14 [26066997.001]
  • [Cites] Toxicol In Vitro. 2015 Feb;29(1):259-70 [25448812.001]
  • [Cites] Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29 [23535119.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):259-71 [25440524.001]
  • [Cites] Nat Biotechnol. 2011 Sep 08;29(9):811-5 [21904331.001]
  • [Cites] Front Pharmacol. 2015 May 27;6:107 [26074819.001]
  • [Cites] Ecotoxicol Environ Saf. 2004 Sep;59(1):1-9 [15261716.001]
  • [Cites] Toxicol Sci. 2011 Dec;124(2):432-45 [21964421.001]
  • [Cites] Toxicol Sci. 2011 Feb;119(2):308-18 [20966114.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37 [25863193.001]
  • [Cites] Toxicol Sci. 2014 Dec;142(2):312-20 [25466378.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Apr;71(3):463-77 [25707856.001]
  • [Cites] Environ Health Perspect. 2014 Dec;122(12):1261-70 [25117432.001]
  • [Cites] Environ Res. 2012 Jul;116:74-84 [22575326.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Nat Biotechnol. 2015 Sep;33(9):933-40 [26258538.001]
  • [Cites] Chem Res Toxicol. 2012 Jul 16;25(7):1287-302 [22519603.001]
  • [Cites] Toxicology. 2015 Jun 5;332:112-23 [25598226.001]
  • [Cites] Environ Mol Mutagen. 2015 Jul;56(6):520-34 [25733247.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):137-54 [26272952.001]
  • [Cites] J Appl Toxicol. 2013 Nov;33(11):1353-64 [23670904.001]
  • [Cites] Altern Lab Anim. 2007 Mar;35(1):25-32 [17411348.001]
  • [Cites] PLoS One. 2016 Jan 12;11(1):e0146594 [26756814.001]
  • [Cites] ALTEX. 2013;30(4):473-86 [24173169.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1318-32 [25820183.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):453-61 [24994890.001]
  • (PMID = 27994170.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES016465
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; AOP / Adverse Outcome Pathways / computational prediction model. / quantitative AOP
  •  go-up   go-down


2. Wang CC, Lin YC, Wang SS, Shih C, Lin YH, Tung CW: SkinSensDB: a curated database for skin sensitization assays. J Cheminform; 2017;9:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SkinSensDB: a curated database for skin sensitization assays.
  • Skin sensitization is an important toxicological endpoint for chemical hazard determination and safety assessment.
  • Prediction of chemical skin sensitizer had traditionally relied on data from rodent models.
  • The development of the adverse outcome pathway (AOP) and associated alternative in vitro assays have reshaped the assessment of skin sensitizers.
  • Current computational models to predict skin sensitization mainly based on in vivo assays without incorporating alternative in vitro assays.
  • However, there are few freely available databases integrating both the in vivo and the in vitro skin sensitization assays for development of AOP-based skin sensitization prediction models.
  • To facilitate the development of AOP-based prediction models, a skin sensitization database named SkinSensDB has been constructed by curating data from published AOP-related assays.
  • In addition to providing datasets for developing computational models, SkinSensDB is equipped with browsing and search tools which enable the assessment of new compounds for their skin sensitization potentials based on data from structurally similar compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2016 Jun 07;11(6):e0155419 [27271321.001]
  • [Cites] Toxicol Sci. 2004 Oct;81(2):332-43 [15254333.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):110-9 [17932397.001]
  • [Cites] Toxicol In Vitro. 2006 Aug;20(5):774-84 [16337770.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Int J Mol Sci. 2009 Jul 17;10(7):3237-54 [19742136.001]
  • [Cites] J Cheminform. 2013 May 21;5:24 [23694746.001]
  • [Cites] Toxicology. 1995 Nov 20;103(1):63-73 [8525491.001]
  • [Cites] J Comput Chem. 2011 May;32(7):1466-74 [21425294.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Anal Chim Acta. 2006 Jul 21;572(2):272-82 [17723489.001]
  • [Cites] J Chem Inf Model. 2005 Jul-Aug;45(4):952-64 [16045289.001]
  • [Cites] J Appl Toxicol. 2016 Sep;36(9):1150-62 [26851134.001]
  • [Cites] Cell Mol Life Sci. 2012 Mar;69(5):763-81 [21997384.001]
  • [Cites] Chem Res Toxicol. 2007 Jan;20(1):114-28 [17226934.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Food Chem Toxicol. 1992 Jan;30(1):65-9 [1544608.001]
  • [Cites] Crit Rev Toxicol. 2010 May;40(5):389-404 [20180632.001]
  • [Cites] Toxicol In Vitro. 2009 Apr;23(3):454-65 [19162165.001]
  • [Cites] Arch Toxicol. 2012 Aug;86(8):1273-95 [22707154.001]
  • [Cites] SAR QSAR Environ Res. 2013;24(12):1009-23 [23988224.001]
  • [Cites] Hum Exp Toxicol. 2015 Dec;34(12):1222-30 [26614809.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):53-69 [18052130.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Jun 15;245(3):281-90 [20307559.001]
  • [Cites] Toxicol Appl Pharmacol. 2015 Apr 15;284(2):262-72 [25560674.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Toxicol In Vitro. 2002 Dec;16(6):711-6 [12423654.001]
  • [Cites] Toxicol Sci. 2007 Oct;99(2):532-44 [17675333.001]
  • [Cites] J Comput Aided Mol Des. 2008 Jun-Jul;22(6-7):345-66 [18338230.001]
  • [Cites] Toxicol Sci. 2009 Nov;112(1):164-74 [19748994.001]
  • [Cites] Nucleic Acids Res. 2015 Jul 1;43(W1):W605-11 [25934803.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1975-86 [26382665.001]
  • (PMID = 28194231.001).
  • [Journal-full-title] Journal of cheminformatics
  • [ISO-abbreviation] J Cheminform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet; 2017 Apr 22;389(10079):1630-1638
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality.
  • We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.
  • The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks.
  • Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed.
  • FUNDING: NIHR Health Technology Assessment Programme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
  • [Cites] Lancet. 2013 Jan 26;381(9863):320-32 [23237497.001]
  • [Cites] Vet Hum Toxicol. 1988 Oct;30(5):431-43 [3055652.001]
  • [Cites] Singapore Med J. 2000 Jul;41(7):327-30 [11026799.001]
  • [Cites] Clin Exp Dermatol. 2013 Apr;38(3):311-3 [23517364.001]
  • [Cites] J Invest Dermatol. 2015 May;135(5):1445-7 [25560279.001]
  • [Cites] Stat Med. 2003 Jan 30;22(2):169-86 [12520555.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):17-8 [26174646.001]
  • [Cites] J Am Acad Dermatol. 2014 Dec;71(6):1191-7 [25174542.001]
  • [Cites] Medicine (Baltimore). 1953 Feb;32(1):1-123 [13024494.001]
  • [Cites] JAMA Dermatol. 2013 Jan;149(1):58-62 [23324757.001]
  • [Cites] J Invest Dermatol. 2012 Aug;132(8):1998-2004 [22418872.001]
  • [Cites] Arch Dermatol. 2010 Nov;146(11):1251-4 [21079062.001]
  • [Cites] Health Technol Assess. 2017 Mar;21(10 ):1-90 [28406394.001]
  • [Cites] J Am Acad Dermatol. 2012 Mar;66(3):479-85 [22056920.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):227-34 [25683592.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):321-7 [11821508.001]
  • [Cites] Lancet. 1984 Sep 1;2(8401):486-8 [6147549.001]
  • [Cites] Clin Exp Dermatol. 2016 Jul;41(5):506-9 [26940484.001]
  • [Cites] BMJ. 2008 Jul 09;337:a180 [18614511.001]
  • [Cites] J Invest Dermatol. 2009 Jul;129(7):1681-7 [19177141.001]
  • [Cites] Br J Dermatol. 2015 Apr;172(4):867-77 [25827742.001]
  • [Cites] Trials. 2012 Apr 27;13:50 [22540678.001]
  • [Cites] Br J Dermatol. 2012 Dec;167(6):1200-14 [23121204.001]
  • [Cites] Br J Dermatol. 2016 Apr;174(4):919-21 [26556709.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Oct 06;(10):CD002292 [20927731.001]
  • [Cites] J Invest Dermatol. 2011 Mar;131(3):637-43 [20944650.001]
  • [Cites] Br J Dermatol. 1979 Nov;101(5):521-34 [391261.001]
  • [Cites] Arch Dermatol. 1994 Jun;130(6):753-8 [8002646.001]
  • [Cites] Pharmacol Res. 2011 Feb;63(2):130-45 [20937386.001]
  • (PMID = 28279484.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Adams J; Akhras V; Anstey A; Barnard C; Bell H; Blackford S; Bröcker E; Carmichael A; Coelho RR; Craig F; Davies K; Ellis R; English J; Gläser R; Groves R; Günthert C; Hampton PJ; Hepburn N; Hügel R; Hussain K; Ingram J; Layton AM; Levell NJ; Lewis V; Malhomme H; Omerod A; Patel G; Rallan R; Ravenscroft J; Santander H; Steinbrink K; Sticherling M; Thomas C; Vatve M; van Beek N; Venning V; Veysey E; Wachsmuth R; Wahie S; Walker B; Walsh M; Wee J; Westmoreland M; Wong G; Ferguson A; Verpetinske I; Duarte-Williamson E; Antony F; Bower C; Gawkrodger D; Taghipour K; Dunnill MGS; Waters A; Bottomley W; Wright A; Sterling J; Azam A; Gibbs S; Luger T; Salvary I; Lovell C; Ilchyshyn A; Gibbon K; Nik M; Charles-Holmes R; Lavery AL
  •  go-up   go-down


Advertisement
4. Attia A, Abushouk AI, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z, Abdel-Daim MM, Negida A: Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Clin Drug Investig; 2017 May;37(5):439-451

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
  • BACKGROUND: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population.
  • We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework.
  • Analysis of secondary outcomes showed that brodalumab was superior to placebo in terms of static physician's global assessment (RR = 32.53, 95% CI 13.80-76.69) and psoriasis symptoms inventory scores (RR = 14.70, 95% CI 8.38-25.78).
  • CONCLUSION: Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197901.001).
  • [ISSN] 1179-1918
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / IL17A protein, human; 0 / Interleukin-17; 0 / brodalumab
  •  go-up   go-down


5. Bitzer J, Römer T, Lopes da Silva Filho A: The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care; 2017 Jun;22(3):172-182
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
  • Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment.
  • OBJECTIVE: To review the data on the efficacy and safety of CPA 2 mg/EE 35 μg for the treatment of hyperandrogenic skin symptoms in women.
  • Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated.
  • Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA).
  • CONCLUSIONS: This review provides a comprehensive overview about the efficacy of CPA 2 mg/EE 35 μg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28447864.001).
  • [ISSN] 1473-0782
  • [Journal-full-title] The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • [ISO-abbreviation] Eur J Contracept Reprod Health Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hyperandrogenism / acne / alopecia / cyproterone acetate / ethinylestradiol / hirsutism / polycystic ovary syndrome / seborrhea
  •  go-up   go-down


6. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S: Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff. BMC Dermatol; 2017 May 03;17(1):5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.
  • The efficacy of each product was evaluated by comparing proportion of subjects who have shown reduction in flaking by ASFS (adherent scalp flaking score) and pruritus by IGA (investigator global assessment) score.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1975 Jun;64(6):401-5 [237965.001]
  • [Cites] J Clin Aesthet Dermatol. 2011 Sep;4(9):22-42 [21938268.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):194-7 [16382662.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [16382685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18730-5 [18000048.001]
  • [Cites] Int J Cosmet Sci. 2006 Oct;28(5):311-8 [18489295.001]
  • [Cites] Br J Dermatol. 1984 Aug;111(2):235-42 [6235835.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):130-4 [20606879.001]
  • [Cites] Int J Cosmet Sci. 2012 Aug;34(4):298-306 [22515370.001]
  • [Cites] J Cosmet Dermatol. 2010 Sep;9(3):202-10 [20883293.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):897-903 [11712036.001]
  • [Cites] Contact Dermatitis. 2002 Jan;46(1):6-12 [11918580.001]
  • [Cites] Mycoses. 2015 Apr;58(4):215-9 [25676074.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1781-6 [10507598.001]
  • [Cites] Arch Dermatol Res. 2002 Jul;294(5):221-30 [12115025.001]
  • (PMID = 28468620.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Anti-fungals / Dandruff / Malassezia / Scalp
  •  go-up   go-down


7. Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N: Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf; 2017 Apr;40(4):317-331

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
  • METHODS: A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug-event pair level with six negative controls.
  • Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria.
  • Of these, 13 posts were selected for causality assessment of product-event pairs.
  • Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product-event associations: dronedarone-vasculitis and Banana Boat Sunscreen--skin burns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Drug Saf. 2015;14(12):1845-53 [26436834.001]
  • [Cites] J Biomed Inform. 2015 Jun;55:73-81 [25817970.001]
  • [Cites] Patient Prefer Adherence. 2015 Jan 23;9:173-84 [25670886.001]
  • [Cites] Drug Saf. 2014 Oct;37(10):761-4 [25096955.001]
  • [Cites] J Med Internet Res. 2015 Jul 10;17(7):e171 [26163365.001]
  • [Cites] J Biomed Inform. 2016 Feb;59:42-8 [26610385.001]
  • [Cites] Nat Rev Rheumatol. 2015 Feb;11(2):119-23 [25314016.001]
  • [Cites] J Biomed Inform. 2011 Dec;44(6):989-96 [21820083.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1161-6 [17486665.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):256-62 [23322591.001]
  • [Cites] J Am Board Fam Pract. 2004 Mar-Apr;17(2):142-9 [15082674.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:202-12 [25720841.001]
  • [Cites] J Clin Pharm Ther. 2014 Feb;39(1):53-5 [24304185.001]
  • [Cites] Drug Saf. 2011 Apr 1;34(4):267-71 [21417499.001]
  • [Cites] Methods Inf Med. 2013;52(2):152-9 [23450374.001]
  • [Cites] Drug Saf. 2016 May;39(5):443-54 [26798054.001]
  • [Cites] Eur J Clin Pharmacol. 2013 Feb;69(2):209-15 [22688722.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):239-46 [24713590.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):910-20 [26147850.001]
  • [Cites] Drug Saf. 2014 Aug;37(8):629-37 [25027671.001]
  • [Cites] Adv Psychobiol. 1974;2:297-312 [4476178.001]
  • [Cites] N Z Med J. 2014 Aug 29;127(1401):69-81 [25225758.001]
  • [Cites] Drug Saf. 2014 May;37(5):343-50 [24777653.001]
  • [Cites] J Biomed Inform. 2015 Feb;53:196-207 [25451103.001]
  • [Cites] J Med Internet Res. 2007 Feb 28;9(1):e4 [17478413.001]
  • [Cites] J Med Internet Res. 2011 May 17;13(2):e37 [21586386.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2153-5, 2157 [19423867.001]
  • [Cites] J Addict Dis. 2015;34(4):303-10 [26364675.001]
  • [Cites] Br J Clin Pharmacol. 1996 Oct;42(4):423-9 [8904613.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):878-88 [26271492.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:230-40 [25688695.001]
  • [Cites] J Am Med Inform Assoc. 2015 May;22(3):671-81 [25755127.001]
  • [Cites] Drug Saf. 1999 Feb;20(2):95-107 [10082068.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):149-50 [25056395.001]
  • [Cites] Drug Saf. 2015 Oct;38(10):921-30 [26242616.001]
  • [Cites] Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903 [24603135.001]
  • [Cites] Trends Pharmacol Sci. 2013 Jul;34(7):357-8 [23759353.001]
  • [Cites] J Antimicrob Chemother. 2014 Sep;69(9):2568-72 [24862092.001]
  • [Cites] AMIA Annu Symp Proc. 2014 Nov 14;2014:924-33 [25954400.001]
  • [Cites] J Nerv Ment Dis. 1972 Nov;155(5):363-5 [5082173.001]
  • (PMID = 28044249.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


8. Puschner B, Bautista AC, Wong C: Debromoaplysiatoxin as the Causative Agent of Dermatitis in a Dog after Exposure to Freshwater in California. Front Vet Sci; 2017;4:50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cases of acute hepato- and neurotoxicoses in dogs following cyanotoxin exposure exist, no reports of skin-related reactions in dogs exist.
  • Assessment of the dog's environment revealed access to a lake on the property with visible algal bloom.
  • Access to the lake was discontinued and follow-up evaluation over the next few weeks revealed a complete resolution of the skin irritation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicon. 2008 Aug 1;52(2):385-8 [18585400.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):554-62 [17585335.001]
  • [Cites] J Vet Emerg Crit Care (San Antonio). 2010 Oct;20(5):518-22 [20955303.001]
  • [Cites] J Am Anim Hosp Assoc. 2013 Sep-Oct;49(5):342-6 [23861261.001]
  • [Cites] Hawaii Med J. 1959 Sep-Oct;19:32-4 [13829055.001]
  • [Cites] Arch Dermatol. 1978 Sep;114(9):1333-5 [686747.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1995 Oct 6;44(39):724-7 [7565550.001]
  • [Cites] Toxicon. 2005 Jun 1;45(7):919-28 [15904687.001]
  • [Cites] BMC Dermatol. 2008 Dec 30;8:5 [19116031.001]
  • [Cites] J Am Chem Soc. 1974 Apr 3;96(7):2245-6 [4833645.001]
  • [Cites] Toxicon. 2012 Nov;60(6):1148-58 [22960450.001]
  • [Cites] BMC Public Health. 2006 Apr 11;6:93 [16606468.001]
  • [Cites] Hawaii Med J. 1982 Jul;41(7):200-1 [7129866.001]
  • [Cites] Arch Dermatol. 1961 Nov;84:720-32 [13901248.001]
  • [Cites] Harmful Algae. 2016 Apr;54:213-222 [28073478.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2703-13 [12928424.001]
  • [Cites] Toxicon. 1996 Jul;34(7):753-61 [8843576.001]
  • [Cites] Chemosphere. 2014 Feb;96:1-15 [24012139.001]
  • [Cites] Mol Nutr Food Res. 2007 Jan;51(1):7-60 [17195276.001]
  • [Cites] J Vet Diagn Invest. 2008 Jan;20(1):89-92 [18182518.001]
  • [Cites] Int J Dermatol. 2012 Jan;51(1):59-62 [21790555.001]
  • [Cites] Science. 1977 Apr 29;196(4289):538-40 [403608.001]
  • [Cites] J Vet Diagn Invest. 1993 Jul;5(3):403-8 [8373855.001]
  • [Cites] Environ Int. 2013 Sep;59:303-27 [23892224.001]
  • [Cites] Environ Toxicol. 2001;16(6):512-6 [11769249.001]
  • [Cites] Sci Total Environ. 2014 Jan 1;466-467:397-403 [23927933.001]
  • [Cites] Environ Health Perspect. 2016 Apr;124(4):477-83 [26383636.001]
  • [Cites] Science. 1983 Dec 16;222(4629):1242-4 [6316505.001]
  • [Cites] Mar Drugs. 2016 Mar 09;14 (3):null [27005635.001]
  • [Cites] Toxicon. 1998 Dec;36(12):1913-20 [9839675.001]
  • [Cites] BMC Vet Res. 2015 Jun 19;11:136 [26087767.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4676-80 [6883326.001]
  • (PMID = 28428958.001).
  • [Journal-full-title] Frontiers in veterinary science
  • [ISO-abbreviation] Front Vet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Lyngbya sp. / cyanobacteria / cyanotoxins / debromoaplysiatoxin / dog / skin irritation / toxicosis
  •  go-up   go-down


9. Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R: A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol; 2017 Jan 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
  • BACKGROUND: Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases.
  • OBJECTIVES: The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0.002% to 5.0%.
  • Safety was assessed as local skin reaction adverse events (LSRAE) grades 3-4.
  • The secondary objective was assessment of efficacy on modified PASI (mPASI) score compared with placebo.
  • The treatment period was four weeks with two-week follow-up with assessment at screening, randomization and once weekly until study end.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107559.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Nam CH, Park BC, Kim MH, Choi EH, Hong SP: The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles. Dermatol Surg; 2017 Feb 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles.
  • BACKGROUND: Low-level light therapy (LLLT) using light-emitting diodes (LEDs) is considered to be helpful for skin regeneration and anti-inflammation.
  • OBJECTIVE: To evaluate the efficacy and safety of 2 types of LLLTs using 660 nm-emitting red LEDs and 411 to 777 nm-emitting white LEDs in the treatment of facial wrinkles.
  • RESULTS: In both groups treated with red and white LEDs, the wrinkle measurement from skin replica improved significantly from baseline at Week 12.
  • In the global assessment of the subjects, the mean improvement score of the red LED group was higher than that of the white LED group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28195844.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Katare OP, Raza K, Wadhwa S, Kumar P, Thotakura N: Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab; 2017 Mar 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To estimate the amount of drug delivery to skin, the scientists have now established techniques for separation of skin layers for the determination of drug concentrations.
  • This forms the basis of pharmacokinetics of drug(s) in skin, i.e., dermatokinetics.
  • Assessment of bioavailability helps in determination of safety and efficacy of topical formulations.
  • As the methods used for determination of pharmacokinetics of oral and intravenous formulations are not useful for dermatokinetic assessment, various methods like tape stripping, microdialysis and vasoconstrictor assays are being used for dermatokinetic assessment.These methods are not only useful to determine the drug concentrations in various skin layers, but can also be used to correlate the toxicity effects of xenobiotics with skin layer concentrations.
  • Despite advantages, there are some challenges in methodologies used for calculation of dermatokinetic parameters for furrows on skin and follicular drug penetration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • (PMID = 28266274.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Pharmacokinetics / confocal microscopy / follicular drug penetration / micro dialysis / tape stripping / trypsin digestion / vasoconstrictor assay
  •  go-up   go-down


12. Watzek N, Berger F, Kolle SN, Kaufmann T, Becker M, van Ravenzwaay B: Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results. Regul Toxicol Pharmacol; 2017 Apr;85:25-32
Hazardous Substances Data Bank. ACETONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results.
  • In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation.
  • This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used.
  • Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.

  • Hazardous Substances Data Bank. Propylene glycol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28159477.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Allergens; 0 / Cyclohexylamines; 0 / Excipients; 0 / Haptens; 0 / Olive Oil; 1364PS73AF / Acetone; 6DC9Q167V3 / Propylene Glycol
  • [Keywords] NOTNLM ; AOO / Adverse Outcome Pathway / BrdU-ELISA / False positive results / Local Lymph Node Assay / Skin sensitization / Test substance stability in the vehicle
  •  go-up   go-down


13. Jacques-Jamin C, Jeanjean-Miquel C, Domergue A, Bessou-Touya S, Duplan H: Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis. Skin Pharmacol Physiol; 2017;30(2):55-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis.
  • BACKGROUND: Information is lacking on the dermal penetration of topically applied formulations on in vitro skin models, under conditions where the stratum corneum (SC) is damaged.
  • Therefore, we have developed a standardized in vitro barrier-disrupted skin model using tape stripping.
  • RESULTS: The effects of tape stripping were comparable using pig and human skin.
  • The bioavailability of the filters was extremely low regardless of the extent of skin damage, suggesting bioavailability would not be increased if the consumer applied the sunscreen to sun-damaged skin.
  • CONCLUSION: This standardized in vitro methodology using pig or human skin for damaged skin will add valuable information for the safety assessment of topically applied products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28278501.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Barrier-disrupted skin model / Bioavailability / Human / Pig / Standardized model / Sunscreen filters / Tape stripping
  •  go-up   go-down


14. Janne PA, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, Khuri F, Liang JQ, O'Connell J, Giaccone G: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.
  • Endpoints include objective response rate, duration of response, progression-free survival, survival, safety/tolerability, and pharmacokinetics.
  • Pharmacodynamic endpoints include assessment of serum levels of HER2 and EGFR extracellular domains.
  • The most common treatment-related AEs were skin and gastrointestinal disorders, with grade 3 AEs in 19% and 13% of pts, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962636.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Chi Y, Zheng Z, Zhou A, Yang L, Qu T, Jiang W, Shi S, Sun Y, Song Y, Kang S, Wang J: Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e21021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21021 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials.
  • The primary endpoint was ORR and the secondary endpoints included TTP, PFS, 1-year survival rates and safety.
  • Up to 2011-01-14, 36 patients (NCS 19 cases compared with CS 17) have undergone efficacy assessment.
  • No adverse events of grade 3 skin rash or grade 3 infusion-related reactions were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Robert F, Verschraegen C, Hurwitz H, Uronis H, Advani R, Chen A, Taverna P, Wollman M, Fox J, Michelson G: A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):2536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints: safety, tolerability, and DLT assessment.
  • Pharmacodynamic endpoint was inhibition of Histone H3 phosphorylation (pHH3) evaluated by immunohistochemistry of skin punch biopsies taken pre- and 2 hours post-infusion.
  • Inhibition of pHH3 by SNS-314 was observed in skin biopsies of patients treated at doses of 240 mg/m<sup>2</sup> and greater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Scotte F, Tourani JM, Banu E, Peyromaure M, Jenabian A, Levy E, Coquelin K, Magherini E, Marsan S, Oudard S: Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study.
  • : 8003 Background: Onycholysis and skin toxicity occur in about 15% of patients (pts) treated with docetaxel (D).
  • We investigated the efficacy and safety of an Elasto-Gel (Akromed, France) flexible frozen glove (FG) for the prevention of D-induced onycholysis and skin toxicity.
  • Onycholysis and skin toxicity were assessed at each cycle by NCI-CTC v.2 criteria and documented by photography.
  • Onycholysis and skin toxicity (main criteria) was significantly lower in the FG protected hand compared with the control hand (p=0.0001, Wilcoxon test).
  • Skin toxicity was G0: 73% vs. 41% and G1-2: 27% vs. 59% in the FG-protected hand and the control hand, respectively.
  • Median time to nail and skin toxicity occurrence was not significantly different between FG-protected and the control hand, respectively [106 days (5 cycles) vs. 58 days (2.7 cycles) for nail toxicity; 57 days vs. 58 days for skin toxicity].
  • CONCLUSIONS: Frozen glove significant reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management for a better patient's quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA: A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endpoints included the proportion of pts who did not have PSA progression for 24 weeks, change in PSA slope/PSADT, and assessment of safety and tolerability.
  • ATN-224 was well tolerated with a few reversible Grade 3/4 neutropenia and Grade 3 skin rash (both 4%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fichtenbaum EJ, Strine AC, Concodora CW, Schulte M, Noh PH: Tubeless outpatient robotic upper urinary tract reconstruction in the pediatric population: short-term assessment of safety. J Robot Surg; 2017 Jun 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubeless outpatient robotic upper urinary tract reconstruction in the pediatric population: short-term assessment of safety.
  • The aim of the study was to assess the safety of performing tubeless robotic UUTR as an outpatient procedure.
  • Median operative time was 167 min (range 108-249), defined as skin incision to closure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28639117.001).
  • [ISSN] 1863-2491
  • [Journal-full-title] Journal of robotic surgery
  • [ISO-abbreviation] J Robot Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ambulatory surgical procedures / Pediatrics / Surgical procedures, robotic / Ureteral obstruction
  •  go-up   go-down


20. Naqi N, Ahmad S, Murad S, Khattak J: A phase II feasibility study of sorafenib and gemcitabine combination therapy in advanced hepatocellular carcinoma. J Clin Oncol; 2011 Feb;29(4_suppl):298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to evaluate the efficacy and safety of sorafenib and gemcitabine combination in advanced HCC.
  • National Cancer Institute criteria for adverse events (NCI CTCAE) Version 3.0, and Response evaluation criteria for solid tumors (RECIST) was used for assessment.
  • 8 patients had progressive disease, 4 progressing on interim assessment were taken off protocol.
  • Sorafenib specific, hand foot skin reaction and anorexia were next most frequent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Api AM, Belsito D, Botelho D, Browne D, Bruze M, Burton GA Jr, Buschmann J, Calow P, Dagli ML, Date M, Dekant W, Deodhar C, Fryer AD, Joshi K, La Cava S, Lapczynski A, Liebler DC, O'Brien D, Parakhia R, Patel A, Penning TM, Ritacco G, Romine J, Salvito D, Schultz TW, Sipes IG, Thakkar Y, Tsang S, Wahler J: RIFM fragrance ingredient safety assessment, acetic acid, C7-9-branched alkyl esters, C8-rich, CAS Registry Number 108419-32-5. Food Chem Toxicol; 2017 May 30;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RIFM fragrance ingredient safety assessment, acetic acid, C7-9-branched alkyl esters, C8-rich, CAS Registry Number 108419-32-5.
  • This material was evaluated for genotoxicity, repeated dose toxicity, developmental and reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, as well as environmental safety.
  • Data from the suitable read across analog isoamyl acetate (CAS# 123-92-2) show that this material does not have skin sensitization potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28576467.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Developmental and reproductive toxicity / Environmental safety / Genotoxicity / Local respiratory toxicity / Phototoxicity/photoallergenicity / Repeated dose / Skin sensitization
  •  go-up   go-down


22. Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung JW, Siedentop H, Molnar I, Schlumberger M: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol; 2013 Jun 20;31(18_suppl):4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The double-blind, randomized, multicenter phase III DECISION trial examined sorafenib efficacy and safety vs placebo in patients with progressive RAI-refractory DTC.
  • Secondary endpoints included overall survival (OS), response rate (RR; complete + partial response [PR]), and safety.
  • Tumor histology by independent assessment was 57% papillary, 25% follicular, and 10% poorly differentiated.
  • The most common any-grade treatment-emergent adverse events in the sorafenib arm included hand-foot skin reaction, diarrhea, alopecia, rash/desquamation, fatigue, weight loss and hypertension.
  • Tolerability was consistent with the known sorafenib safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28136058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Bil W, Schuur AG, Ezendam J, Bokkers BGH: Probabilistic derivation of the interspecies assessment factor for skin sensitization. Regul Toxicol Pharmacol; 2017 May 22;88:34-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probabilistic derivation of the interspecies assessment factor for skin sensitization.
  • An interspecies sensitization assessment factor (SAF) is used in the quantitative risk assessment (QRA) for skin sensitization when a murine-based NESIL (No Expected Sensitization Induction Level) is taken as point of departure.
  • It can be concluded that a murine-based NESIL requires the use of an interspecies SAF (of 15) in the QRA for skin sensitization, to correct for the differences between mice and humans.
  • This empirically derived interspecies SAF contributes to refinement of the risk assessment methodology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28545776.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Allergic contact dermatitis / Dose-response modeling / HMT / HRIPT / Interspecies sensitization assessment factor / LLNA / Probability distribution / Quantitative risk assessment / Skin sensitization
  •  go-up   go-down


24. Thiesen LC, Baccarin T, Fischer-Muller AF, Meyre-Silva C, Couto AG, Bresolin TM, Santin JR: Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract. J Photochem Photobiol B; 2017 Feb;167:200-207
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract.
  • Actually, there has been an increase in the use of natural products as skin photoprotective agents.
  • Data herein obtained pointed out the potential of L. chinensis extract for photochemoprotection against UVA/UVB radiation and its damaging effects on human skin.
  • [MeSH-major] DNA Damage / drug effects. Litchi / chemistry. Plant Extracts / pharmacology. Plant Leaves / chemistry. Safety. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Safety.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28086120.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Extracts; BBX060AN9V / Hydrogen Peroxide
  • [Keywords] NOTNLM ; Irritant / Litchi chinensis / Photochemoprotection / Photohaemolysis / Phototoxicity
  •  go-up   go-down


25. Clouet E, Kerdine-Römer S, Ferret PJ: Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references. Toxicol In Vitro; 2017 May 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references.
  • Allergic contact dermatitis (ACD) is an adverse health effect that develops following repeated exposure to skin sensitizing chemicals.
  • Here, we have selected an ITS (Integrated Testing Strategy) for skin sensitization which focuses on three in vitro methods that covered the first three steps of the AOP (DPRA, SENS-IS or h-CLAT).
  • The aim of this study was to compare these three methods due to the WoE approach based on a 2-out-of-3-assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier Ltd.
  • (PMID = 28539215.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; AOP / DPRA / ITS / SENS-IS / Skin sensitization / h-CLAT
  •  go-up   go-down


26. Munavalli G: A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients. J Drugs Dermatol; 2016 Nov 01;15(11):1335-1342

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients.
  • Recent appreciation of the multifactorial pathophysiology of skin aging has led to increased use of parallel treatment regimens.
  • This prospective, split-face, randomized study assessed the safety and efficacy of same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST) facial rejuvenation treatment in comparison to fractional non-ablative laser (NAFL) treatment only.
  • Immediate skin responses were assessed within 30 minutes of treatment, while wrinkle/elastosis scores, and skin tone and texture were evaluated 1, 3, and 6 months following the final treatment session.
  • Physician-evaluated skin tone and patient ratings of skin texture and overall improvement of the SST-treated side were consistently higher than the contralateral NAFL-treated side.
  • Although the SST regimen failed to demonstrate statistically signi cant clinical superiority over the NAFL regimen, the significantly lower pain levels, consistently higher physician and patient ratings following SST may justify its regular use as a skin rejuvenation technique.
  • [MeSH-major] Cosmetic Techniques. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Low-Level Light Therapy / methods. Rejuvenation. Skin Aging
  • [MeSH-minor] Aged. Combined Modality Therapy / adverse effects. Female. Follow-Up Studies. Humans. Middle Aged. Pain / etiology. Skin Pigmentation / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095544.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Johnson W Jr, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Anthemis nobilis-Derived Ingredients as Used in Cosmetics. Int J Toxicol; 2017 May/Jun;36(1_suppl):57S-66S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Anthemis nobilis-Derived Ingredients as Used in Cosmetics.
  • Anthemis nobilis (Roman chamomile) flower extract, anthemis nobilis flower oil, anthemis nobilis flower powder, and anthemis nobilis flower water are ingredients that function as fragrance ingredients and skin-conditioning agents in cosmetic products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28553737.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anthemis nobilis / cosmetics / safety
  •  go-up   go-down


28. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This phase 2 study assessed the efficacy and safety of ABX-EGF monotherapy in pts with mCRC who previously failed therapy with a fluoropyrimidine and irinotecan or oxaliplatin or both.
  • Of 148 pts with evaluations after 8 weeks, 15 (10.1%; 95%CI: 5.8%, 16.2%) had confirmed partial responses (12 cohort A, 3 cohort B) and 54 (36.5%) had stable disease (39 cohort A, 15 cohort B) by investigator assessment.
  • The most frequent adverse event (AE) was skin rash (> 90%) [3.4% grade 3].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Zhang W, Chen L, Chen J, Wang L, Gui X, Ran J, Xu G, Zhao H, Zeng M, Ji J, Qian L, Zhou J, Ouyang H, Zou X: Silk Fibroin Biomaterial Shows Safe and Effective Wound Healing in Animal Models and a Randomized Controlled Clinical Trial. Adv Healthc Mater; 2017 May;6(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here a silk fibroin film is developed and its translational potential is investigated for skin repair by performing comprehensive preclinical and clinical studies to fully evaluate its safety and effectiveness.
  • In vivo rabbit full-thickness skin defect study shows that the silk fibroin film effectively reduces the average wound healing time with better skin regeneration compared with the commercial wound dressings.
  • Subsequent assessment in porcine model confirms its long-term safety and effectiveness for full-thickness skin defects.
  • Therefore, the study provides systematic preclinical and clinical evidence that the silk fibroin film promotes wound healing thereby establishing a foundation towards its application for skin repair and regeneration in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28337854.001).
  • [ISSN] 2192-2659
  • [Journal-full-title] Advanced healthcare materials
  • [ISO-abbreviation] Adv Healthc Mater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; bench to bedside / controlled clinical trial / silk fibroin biomaterial / skin repair and regeneration / wound healing
  •  go-up   go-down


30. Dornic N, Ficheux AS, Bernard A, Roudot AC: Adequacy of the default values for skin surface area used for risk assessment and French anthropometric data by a probabilistic approach. Food Chem Toxicol; 2017 Jun 08;106(Pt A):386-392

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequacy of the default values for skin surface area used for risk assessment and French anthropometric data by a probabilistic approach.
  • The notes of guidance for the testing of cosmetic ingredients and their safety evaluation by the Scientific Committee on Consumer Safety (SCCS) is a document dedicated to ensuring the safety of European consumers.
  • This contains useful data for risk assessment such as default values for Skin Surface Area (SSA).
  • Probabilistic treatment of these data and analysis of the case of methylisothiazolinone, a sensitizer recently evaluated by a deterministic approach submitted to SCCS, suggest that the default value for SSA used in the quantitative risk assessment might not be relevant for a significant share of the French female population.
  • This is of importance given that some studies show an increasing risk of developping skin sensitization among women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28602598.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Steiner A, Kugarajan K, Wullimann M, Ruty B, Kunze G: Margin of safety of pentylene glycol derived using measurements of cutaneous absorption and volatility. Regul Toxicol Pharmacol; 2017 Jul;87:106-111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety of pentylene glycol derived using measurements of cutaneous absorption and volatility.
  • The safety assessment of pentylene glycol (PG) has been based on a bioavailability extrapolated from those of other 1,2-glycols or an assumed 100% absorption.
  • To make a better safety assessment and an accurate calculation of the margin of safety (MoS), the skin penetration of PG present in a commercially available sunscreen was measured in pig skin at different exposure durations.
  • The mass balance of PG decreased with increasing exposure durations, from 98% (1 h) to 29% (24 h) and the amount of PG detected in the skin wash decreased over time from 93% to 3%.
  • MoS values for the application of a standard dose of sunscreen after 1-24 h exposure were 140-671 in adults and, if calculated for children ratios, 87-217 Based on the available toxicological data for PG in comparison to the amounts determined to be potentially bioavailable, PG in the test sun protection product SPF 50 + does not show any safety concerns for daily usage at the recommended dosage of 2 mg/cm<sup>2</sup> or lower.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28483712.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Margin of safety / Pentylene glycol / Safety assessment / Skin penetration / Sunscreen / Volatile
  •  go-up   go-down


32. Musazzi UM, Franzè S, Minghetti P, Casiraghi A: Emulsion versus nanoemulsion: how much is the formulative shift critical for a cosmetic product? Drug Deliv Transl Res; 2017 May 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, nanoemulsions seemed to improve the penetration of active ingredients through the human skin, comparing to conventional emulsion.
  • In this contest, the risk of a higher systemic exposure of consumer to active ingredients, due to the ability of nanoemulsion to enhance permeation, results a critical attribute that should be evaluated for assuring the consumer safety.
  • The aim of this work was the evaluation of how an oil-in-water (O/W) nanoemulsion can influence the in vitro skin permeation profiles of two model active ingredients with different polarity (i.e., caffeine and ethyl ximenynate).
  • Considering such findings, it is worth observing that there is room for reconsidering the risk assessment of nanoemulsion-based cosmetic products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28508377.001).
  • [ISSN] 2190-3948
  • [Journal-full-title] Drug delivery and translational research
  • [ISO-abbreviation] Drug Deliv Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Caffeine / Cosmetic / Ethyl ximenynate / Nanoemulsion / Risk assessment
  •  go-up   go-down


33. Jubbal KT, Zavlin D, Buchanan EP, Hollier LH Jr: Analysis of risk factors associated with unplanned reoperations following pediatric plastic surgery. J Plast Reconstr Aesthet Surg; 2017 May 18;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: Unplanned reoperation (UR) is an outcome measure with multiple advantages that can be used as a standardized tool to assess an institution's quality and safety of medical care.
  • The procedures most commonly associated with UR were excision of skin and subcutaneous tissue for hidradenitis (UR = 10.3%), forehead, and/or supraorbital rim reconstruction with grafts (allograft or prosthetic material, UR = 6.1%), use of multiplane external fixators (UR = 5.6%), mastectomy for gynecomastia (UR = 4.4%), and forehead and/or supraorbital rim reconstruction with autograft (3.3%).
  • These results may aid in the informed consent process, improve patient risk assessment, counseling, and surgical planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28595843.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Outcomes / Pediatric / Plastic surgery / Reoperation
  •  go-up   go-down


34. Friedman PM, Tolkachjov SN, Geddes ER, Tillman KA, Zachary CB: TRASER: An innovative device for the treatment of nasal telangiectasias. Lasers Surg Med; 2017 Apr 06;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
  • METHODS: Fifteen subjects aged 42-73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes.
  • Efficacy was measured by blinded analysis of pre and post images and self-assessment by the subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382712.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TRASER / Total Reflection Amplification of Spontaneous Emission Radiation / pulse dye laser / pyrromethene / telangiectasias / total internal reflection / tunable wavelength / variable pulse duration
  •  go-up   go-down


35. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ: Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol; 2011 May 20;29(15_suppl):TPS124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most drug-related adverse events were grade 1/2 in severity with the exception of grade 3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in PL+CAP).
  • Radiographic assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter.
  • Secondary endpoints include overall survival, time to progression, overall response rate, duration of response (RECIST 1.1 criteria), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Shen Y, Hsu C, Hsu C, Lin Z, Chen P, Shao Y, Huang T, Ding Y, Cheng A: A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II study to evaluate the efficacy and safety of sorafenib plus low-dose UFT in advanced HCC patients (pts).
  • Tumor assessment was performed q8w by RECIST criteria.
  • Hand-foot skin reaction (HFSR), fatigue, and diarrhea were most common AEs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Politi Y, Levi A, Lapidoth M: Integrated Cooling-Vacuum-Assisted Non-Fractional 1540 nm Erbium:Glass Laser is Effective in Treating Acne Scars. J Drugs Dermatol; 2016 Nov 01;15(11):1359-1363

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mid-infrared laser skin interaction is characterized by its modest absorption in water and nite penetration to the mid-dermis.
  • OBJECTIVES: To evaluate the safety and efficacy of acne scars treatment using an integrated cooling-vacuum-assisted 1540 nm Erbium: Glass Laser.
  • Average improvement was 3.9 and 4.1 points on the quartile scale used for outcome assessment 1 and 3 months following the last session, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095548.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J: EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. Endocr Pract; 2017 May;23(5):557-565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
  • This study aimed to evaluate the efficacy and safety of testosterone gel 2% (Tgel) over 90 days.
  • Safety endpoints were adverse events (AEs), laboratory parameters, and vital signs.
  • Tgel had a favorable local skin tolerability profile.
  • Symptoms of testosterone deficiency improved with few safety concerns.
  • ABBREVIATIONS: AE = adverse event C<sub>ave(0-24)</sub> = average testosterone concentration CI = confidence interval C<sub>max</sub> = maximum concentration IIEF = International Index of Erectile Function MAF = Multidimensional Assessment of Fatigue PK = pharmacokinetic PSA = prostate-specific antigen SAE = serious adverse event SF-12 = Short Form 12 Health Survey Tgel = testosterone gel 2% T<sub>max</sub> = time to achieve maximum concentration TRT = testosterone replacement therapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28225313.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Dall'oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G: A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: a open-label trial utilizing clinical evaluation and erythemadirected digital photography. G Ital Dermatol Venereol; 2017 Jan 24;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced digital photography, equipped with technology able to provide a detailed evaluation of red skin components corresponding to vascular flare (erythema-directed digital photography), is a useful tool for evaluation of erythema in patients affected by inflammatory dermatoses.
  • The aim of this study was to assess the efficacy and safety of a new cosmetic topical gel containing ciclopiroxolamine, lactoferrin, glycero-phosphoinositol (GPI) and Aloe vera, for the treatment of facial seborrheic dermatitis by clinical and advanced digital photography evaluation.
  • Finally, at baseline and at the end of the study IGA (Investigator Global Assessment) was performed using a 5-point severity scale (from 0 =worsening to 4= excellent response).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121079.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol; 2011 May 20;29(15_suppl):3004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib.
  • In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD.
  • Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Of the 112 pts with RCC, 65 pts have reached the initial 12-week assessment (63 evaluable for response).
  • The randomized portion will provide information about BAY's disease-stabilizing effect and long-term safety, in particular in pts with RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Campbell K, Baker B, Tovar A, Economos E, Williams B, McCauley L: The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers. Workplace Health Saf; 2017 Jul;65(7):313-321

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers.
  • The objective of this study was to assess work-related hygiene practices and the frequency and location of skin rashes due to cutaneous contact with crop-associated materials (e.g., pesticides) for female nursery and fernery workers in Central Florida.
  • A cross-sectional, community-based participatory research study of 237 female nursery and fernery workers between the ages of 19 and 43 years with significant cutaneous contact with foliage crops was conducted using a self-report questionnaire and a skin rash chart assessment tool.
  • Further research is needed to better understand the development of skin rashes among farmworkers, to generate effective prevention strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28628754.001).
  • [ISSN] 2165-0969
  • [Journal-full-title] Workplace health & safety
  • [ISO-abbreviation] Workplace Health Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; disease prevention / government regulation / occupational hazards / occupational health and safety programs / workforce
  •  go-up   go-down


43. Guarneri A, Cioni M, Rongioletti F: High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol; 2017 Mar 29;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of high-dose intravenous immunoglobulin (IVIg) for the management of scleromyxoedema prospectively using an objective score.
  • The patients were followed-up to a minimum of 6 months, and their disease activity and response to treatment were assessed using the Physician's Global Assessment of disease severity (PGA) and a modified objective skin scoring system for patients with scleroderma (modified Rodnan score system for scleromyxoedema or mRSSS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28370513.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Duvic M, Ziari S, Olsen EA, Foss FM: Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6733

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells.
  • Clinical response was determined each course using a weighted composite of disease assessment from baseline.
  • Safety visits were conducted weekly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Monastirli A, Pasmatzi E, Badavanis G, Tsambaos D: Gestational Pityriasis Rosea: Suggestions for Approaching Affected Pregnant Women. Acta Dermatovenerol Croat; 2016 Dec;24(4):312-313

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All miscarrying women reportedly revealed an aggressive course of widespread eruption and severe constitutional symptoms; all of them had HHV-6 DNA in the plasma, placenta, skin lesions, and fetal tissues, whereas HHV-7 DNA was detected in the plasma and skin lesions in 3 out of 8 (37.5%) miscarrying women.
  • HHV-6 DNA was found only in the plasma of 2 out of 31 women (6.45%) with normal pregnancy, whereas HHV-7 DNA was detected in the plasma of 3 (9.45%) and in the skin lesions of 2 women (6.45%) with normal pregnancy.
  • 4. Reliable and definite data from adequate and controlled human studies on the safety of acyclovir or valacyclovir in pregnant women and their efficacy in pityriasis rosea are lacking.
  • Thus, the decision on whether these antiviral compounds will be administered should be tailored to each individual pregnant woman, subsequent to a meticulous assessment of the potential risks and their balancing against the potential benefits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128088.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


46. Zapletalova A, Pata V, Janis R, Kejlova K, Stoklasek P: Objective measurements of skin surface roughness after microdermabrasion treatment. Skin Res Technol; 2017 Jan 12;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective measurements of skin surface roughness after microdermabrasion treatment.
  • BACKGROUND: The aim of this article is to present a new methodology for assessment of skin topology using a three-dimensional image (3D).
  • METHODS: The measurement of the skin surface roughness is based on 3D scanning of silicone replicas by chromatic aberration length technique in a contactless manner, i.e. by a polychromatic light beam.
  • Analysis of the skin surface reprints was performed using Talymap, Gold version.
  • Results were analysed by fractal geometry, which allows to evaluate changes of the skin surface before and after application of cosmetics and instrumental cosmetological techniques.
  • The methodology was applied for objective assessment of the effects of diamond microdermabrasion on the skin surface roughness.
  • RESULTS: Based on the results of skin surface scanning after the treatment with diamond microdermabrasion it may be concluded that inequalities of the skin surface are reduced immediately after exfoliation.
  • The entire study ultimately suggests that the instrumental method used only leads to improvement of the skin surface immediately after its application.
  • Thermo vision images of the skin surface temperature were obtained during the application of the abrasive method.
  • The experimental results showed that the skin is rather cooled than heated by the treatment.
  • CONCLUSION: This study is focused on the development of a methodology for objective measurement of changes in treated skin relief using 3D scanning.
  • The output may also include also an enlarged model of the skin surface made by 3D printer, which can serve for illustrative communication with the client.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28083897.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3D scanning / claim substantiation / microdermabrasion / replication / skin structure / statistics
  •  go-up   go-down


47. Petry T, Bosch A, Coste X, Eigler D, Germain P, Seidel S, Jean PA: Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes. Regul Toxicol Pharmacol; 2017 Mar;84:64-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes.
  • The skin sensitization potential of chemicals has traditionally been evaluated in vivo according to OECD testing guidelines in guinea pigs or the mouse local lymph node assay.
  • There has lately been a great emphasis on establishing in vitro test methods reflecting the key biological events in the adverse outcome pathway (AOP) for skin sensitization as published by the OECD.
  • Against this background, a group of 8 polysiloxanes and silanes, seven of them aminofunctionalised, for which in vivo data were already available, has been tested in vitro in the direct peptide reactivity assay (DPRA), the KeratinoSens™ and the human cell line activation test (h-CLAT) and in the modified myeloid U937 skin sensitization test (mMUSST) as far as technically feasible.
  • The data also allow for a preliminary evaluation of proposed integrated testing strategies (ITS) to determine the skin sensitization potential of chemicals which were not considered in the training sets of the respective ITS.
  • [MeSH-major] Biological Assay. Dendritic Cells / drug effects. Dermatitis, Allergic Contact / etiology. Irritants / toxicity. Keratinocytes / drug effects. Silanes / toxicity. Siloxanes / toxicity. Skin Irritancy Tests / methods
  • [MeSH-minor] Animal Testing Alternatives. Animals. Feasibility Studies. Gene Expression Regulation / drug effects. Genes, Reporter. Guinea Pigs. Humans. Local Lymph Node Assay. Mice, Inbred CBA. Risk Assessment. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28017767.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Irritants; 0 / Silanes; 0 / Siloxanes
  • [Keywords] NOTNLM ; DPRA (major topic) / GPMT (major topic) / In vitro (major topic) / KeratinoSens™ (major topic) / LLNA (major topic) / Polysiloxanes (major topic) / Sensitization (major topic) / Silanes (major topic) / h-CLAT (major topic) / mMUSST (major topic)
  •  go-up   go-down


48. Jaffray D, Mutic S, Fallone B, Raaymakers B: MO-A-WAB-01: MRI-Guided Radiation Therapy. Med Phys; 2013 Jun;40(6Part23):390

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of integrating a magnetic resonance imaging (MRI) scanner with a therapy radiation source, either a therapy linear accelerator (linac) or <sup>60</sup> Co, emerged as a feasible novel approach for MRI-guided radiation therapy (i.e.
  • MRI offers the capability to visualize soft-tissue as well as to perform physiological assessment of healthy and tumor tissues.
  • Multiple interdependent issues need to be resolved in order to achieve the optimal operation of the MRI scanner and the radiation source(s) such as: a) radiofrequency (RF) interference, b) magnetic field coupling, c) perturbation of the dose deposited in tissue due to the presence of an external magnetic field, and d) escalation of patient skin dose.
  • They will also discuss key aspects related to the clinical implementation of their systems such as safety, applications, workflows, quality control, staffing models for supporting the infrastructure, and preliminary data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28518368.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Dosimetry / Linear accelerators / Magnetic fields / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Radiation treatment / Radiotherapy sources / Tissues
  •  go-up   go-down


49. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P: Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med; 2017 May;83(8):710-717

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECa 233, a standardized extract of <i>Centella asiatica</i>, has been found to exhibit various positive neurological effects and to have a good safety profile.
  • The results showed that all animals had a good tolerability for ECa 233, whereas madecassic and asiatic acids were found in negligible amounts after pharmacokinetic assessment.
  • Both triterpenoids were extensively distributed in the brain, stomach, and skin within 1 h and remained there for at least 4 h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 27992940.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S: [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch]. Hautarzt; 2016 Dec 15;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
  • OBJECTIVES: For lack of clinical safety data, preclinical tests for cutaneous cytotoxicity and calculations for systemic bioavailability after topical application have been performed.
  • CONCLUSION: The present data cannot fully remove safety concerns for topical application of chloral hydrate in the formulation favoured by the NRF (Neues Rezepturformularium)-the so-called 1‑2-3-cream.
  • For a better assessment of harmlessness, tests for cutaneous bioavailability (concentration-time profile) on human skin and clinical studies would be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27981385.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Journal Article; English Abstract
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration / Antipruritics / Bioavailability / Cytotoxicity / Psoriasis
  •  go-up   go-down


51. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, Lauber C: Biology, evolution, and medical importance of polyomaviruses: An update. Infect Genet Evol; 2017 Jun 17;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In immunosuppressed individuals, reactivation of polyomavirus BK or JC can cause serious disease of the urogenital tract and brain, respectively, while Merkel cell polyomavirus is most probably associated with the development of a highly aggressive neuroendocrine skin tumour in elderly or patients with pre-existing conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier B.V.
  • (PMID = 28634106.001).
  • [ISSN] 1567-7257
  • [Journal-full-title] Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • [ISO-abbreviation] Infect. Genet. Evol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Disease / Evolution / Interactome / Phylogeny / Prevalence / Replication
  •  go-up   go-down


52. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger HF, Oruzio DV, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf HW, Mittermueller J, Haberl C, Giessen CA, Moosmann N, Stintzing S: Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. J Clin Oncol; 2011 May 20;29(15_suppl):3589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
  • : 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC).
  • Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab.
  • The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy.
  • RESULTS: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy.
  • While cetuximab-specific skin toxicity such as acneiform rash, dry skin and others occurred in >90% of patients, Cape-ST, predominantly hand-foot syndrome, was observed in only 33.2% of patients.
  • CONCLUSIONS: This analysis supports the hypothesis that for the evaluated regimens a correlation exists between capecitabine-specific skin toxicity and treatment efficacy regarding DCR, PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC, IRIS trial participants: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat; 2017 Jun 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit.
  • Secondary endpoints included safety, tolerability, and pharmacodynamic end points.
  • RESULTS: Twenty-seven women were recruited, four discontinued treatment without response assessment.
  • The most frequently reported grade 3/4 toxicities were dry skin (28%), nausea (13%), fatigue (13%), diarrhoea (8%), headache (7%), anorexia (7%) and lethargy (7%).
  • CONCLUSIONS: The addition of Irosustat to aromatase inhibitor therapy resulted in clinical benefit with an acceptable safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28612226.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Aromatase / Breast cancer / Endocrine therapy / Sulfatase
  •  go-up   go-down


54. Gage R, Leung W, Stanley J, Reeder A, Barr M, Chambers T, Smith M, Signal L: Clothing Protection from UVR: A New Method for Assessment. Photochem Photobiol; 2017 Jun 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clothing Protection from UVR: A New Method for Assessment.
  • Clothing modifies ultraviolet radiation exposure from the sun, and has an impact on skin cancer risk and the endogenous synthesis of vitamin D<sub>3</sub> .
  • Diagrams displaying each clothing item were developed and incorporated into a coverage assessment procedure (CAP).
  • Values of clothing coverage, inter-rater reliability and assessment time were compared between CAP and Lund & Browder methods.
  • Its use could improve comparability between sun-safety studies and aid in quantifying the health effects of ultraviolet radiation exposure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28608526.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Yu Y, Li L, Li H, Yu X, Zhang Y, Wang Q, Zhou Z, Gao D, Ye H, Lin B, Ma R: In vivo assessment of dermal adhesion, penetration, and bioavailability of tetrabromobisphenol A. Environ Pollut; 2017 Sep;228:305-310

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo assessment of dermal adhesion, penetration, and bioavailability of tetrabromobisphenol A.
  • The skin adhesion coefficient (AC) was calculated using a difference-value method and ranged from 0.12 to 3.25 mg/cm<sup>2</sup> and 0.1 to 2.56 mg/cm<sup>2</sup> for the male and female rats, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28550799.001).
  • [ISSN] 1873-6424
  • [Journal-full-title] Environmental pollution (Barking, Essex : 1987)
  • [ISO-abbreviation] Environ. Pollut.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Adhesion / Bioavailability / Dermal exposure / Penetration / Tetrabromobisphenol A
  •  go-up   go-down


56. Derby BM, Codner MA: Evidence-Based Medicine: Face Lift. Plast Reconstr Surg; 2017 Jan;139(1):151e-167e

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3. Incorporate risk-reduction strategies during preoperative assessment.
  • 6. Incorporate use of valid patient outcomes assessment tools in their practice to facilitate standardized outcomes reporting in the face-lift literature.
  • SUMMARY: Treating the aged face requires an understanding of bone and soft-tissue anatomy, including the analogous lamellar layers of the face and neck, and the techniques designed to restore youthful skin tone and facial contours.
  • [MeSH-minor] Evidence-Based Medicine. Face / anatomy & histology. Facial Nerve / anatomy & histology. Female. Humans. Male. Patient Safety. Postoperative Complications / prevention & control. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28027252.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


57. Lai PM, Collaku A, Reed K: Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial. J Int Med Res; 2017 Apr;45(2):647-661
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial.
  • Secondary outcomes included pain relief (PR); PI; time to onset of PR, meaningful PR, cooling, and complete recovery; PI difference; sum of PI difference; total PR; reduction in ankle swelling; and the patient's global assessment of response to treatment.
  • There was a higher incidence of skin and application-site events with 1% diclofenac/3% menthol than with placebo or 1% diclofenac.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28345425.001).
  • [ISSN] 1473-2300
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ankle sprain / diclofenac / menthol / pain / topical administration
  •  go-up   go-down


58. Roberts DW, Aptula A, Api AM: Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis. Chem Res Toxicol; 2017 Feb 20;30(2):524-531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Epoxides are known or proposed to be involved in skin sensitization in various ways.
  • To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of S<sub>N</sub>2 electrophiles.
  • The epoxide QMM predicts the potency of a nonepoxide S<sub>N</sub>2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar S<sub>N</sub>2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121139.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, Danilenko DM, Arora P, Wang X, Ouyang W: IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice. PLoS One; 2017;12(1):e0170639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mechanistically, when compared to other growth factors such as VEGF and PDGF that accelerate wound healing in this model, IL-22 uniquely induced genes involved in reepithelialization, tissue remodeling and innate host defense mechanisms from wounded skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Jan 12;104(1):9-19 [11163236.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Cytokine. 2013 Jun;62(3):360-8 [23582717.001]
  • [Cites] J Invest Dermatol. 2012 Jun;132(6):1717-24 [22358061.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):1080-7 [16936280.001]
  • [Cites] J Invest Dermatol. 2015 Nov;135(11):2862-70 [26168231.001]
  • [Cites] Biologics. 2008 Mar;2(1):1-12 [19707423.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3545-9 [11564763.001]
  • [Cites] Nat Rev Immunol. 2014 Dec;14(12):783-95 [25421700.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Am J Surg. 1998 Aug;176(2A Suppl):48S-54S [9777972.001]
  • [Cites] Sci Transl Med. 2014 Feb 12;6(223):223ra22 [24523322.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1545-51 [12737879.001]
  • [Cites] Nature. 2014 Oct 9;514(7521):237-41 [25119041.001]
  • [Cites] Wound Repair Regen. 2007 Sep-Oct;15(5):665-70 [17971012.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1235-46 [2356856.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7341-7 [11706020.001]
  • [Cites] BMC Microbiol. 2008 Mar 06;8:43 [18325110.001]
  • [Cites] Nat Immunol. 2011 Aug 28;12(10):941-8 [21874025.001]
  • [Cites] Organogenesis. 2011 Jul-Sep;7(3):202-8 [22041517.001]
  • [Cites] Sci Transl Med. 2011 Dec 14;3(113):113ra126 [22174314.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47517-23 [12351624.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1736-43 [16291068.001]
  • [Cites] World J Diabetes. 2014 Aug 15;5(4):546-56 [25126400.001]
  • [Cites] Surgeon. 2007 Aug;5(4):219-31 [17849958.001]
  • [Cites] Front Biosci. 2004 Jan 01;9:283-9 [14766366.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31335-9 [10875937.001]
  • [Cites] Nat Med. 2008 Mar;14(3):275-81 [18264110.001]
  • [Cites] J Invest Dermatol. 2013 May;133(5):1321-9 [23223145.001]
  • [Cites] Nat Med. 2008 Mar;14(3):282-9 [18264109.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1219-22 [17476353.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1719-24 [16291066.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):234-44 [10951241.001]
  • [Cites] Wound Repair Regen. 2004 Jul-Aug;12(4):485-92 [15260814.001]
  • [Cites] Clin Dermatol. 2007 Jan-Feb;25(1):9-18 [17276196.001]
  • [Cites] Bioinformatics. 2007 Jan 15;23(2):257-8 [17098774.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):1935-47 [15161630.001]
  • [Cites] J Biomed Biotechnol. 2011;2011:969618 [21151647.001]
  • [Cites] World J Diabetes. 2015 Feb 15;6(1):37-53 [25685277.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1725-35 [16291067.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2229-40 [17277128.001]
  • [Cites] Clin Plast Surg. 2003 Jan;30(1):1-12 [12636211.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3695-702 [15749908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 25;107(21):9546-51 [20460310.001]
  • [Cites] Wound Repair Regen. 2008 Sep-Oct;16(5):585-601 [19128254.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1309-23 [16619290.001]
  • [Cites] Immunity. 2008 Apr;28(4):454-67 [18400188.001]
  • (PMID = 28125663.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Sugino M, Hatanaka T, Todo H, Mashimo Y, Suzuki T, Kobayashi M, Hosoya O, Jinno H, Juni K, Sugibayashi K: Safety evaluation of dermal exposure to phthalates: Metabolism-dependent percutaneous absorption. Toxicol Appl Pharmacol; 2017 Aug 01;328:10-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety evaluation of dermal exposure to phthalates: Metabolism-dependent percutaneous absorption.
  • When dibutyl phthalate was applied to the skin of hairless rats and humans, only monobutyl phthalate appeared through the skin, and the permeability of the skin was higher than that after the application of the monoester directly.
  • The inhibition of skin esterases made the skin impermeable to the metabolite following dermal exposure to dibutyl ester, whereas removal of the stratum corneum from the skin did not change the skin permeation behavior.
  • The skin permeability of monobenzyl phthalate was higher than that of monobutyl phthalate in humans, although the reverse was observed in rats.
  • Species difference in skin permeation profile corresponded to the esterase activity of the skin homogenate.
  • Di(2-ethylhexyl) phthalate, which was not metabolized by esterases in the skin, was not transported across the skin.
  • Skin metabolism is essential to the percutaneous absorption of phthalates.
  • [MeSH-major] Environmental Pollutants / toxicity. Phthalic Acids / toxicity. Skin Absorption
  • [MeSH-minor] Animals. Dibutyl Phthalate. Diethylhexyl Phthalate / administration & dosage. Diethylhexyl Phthalate / pharmacokinetics. Diethylhexyl Phthalate / toxicity. Environmental Exposure. Esterases / antagonists & inhibitors. Female. Humans. In Vitro Techniques. Male. Middle Aged. Plasticizers / administration & dosage. Plasticizers / pharmacokinetics. Plasticizers / toxicity. Rats. Rats, Hairless. Risk Assessment. Skin / enzymology. Species Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28506834.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Phthalic Acids; 0 / Plasticizers; 131-70-4 / monobutyl phthalate; 2286E5R2KE / Dibutyl Phthalate; C42K0PH13C / Diethylhexyl Phthalate; EC 3.1.- / Esterases; YPC4PJX59M / butylbenzyl phthalate
  • [Keywords] NOTNLM ; Dermal exposure / Metabolism / Phthalates / Risk identification / Skin permeation
  •  go-up   go-down


61. Farah J, Trianni A, Carinou E, Dabin J, Deangelis C, Domienik J, Knezevic Z, Kopec R, Malchair F, Negri A, Novak L, Siiskonen T, Vanhavere F, Clairand I: SU-E-I-28: Assessment of Maximum Patient Skin Dose for Interventional Radiology Procedures: Method and Uncertainty Analysis. Med Phys; 2013 Jun;40(6Part5):131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SU-E-I-28: Assessment of Maximum Patient Skin Dose for Interventional Radiology Procedures: Method and Uncertainty Analysis.
  • PURPOSE: To develop a method for the assessment of patient's maximum skin dose in interventional radiology procedures.
  • METHODS: In the framework of EURADOS WG12, a European measurement protocol was developed to determine fluoroscopy patient skin dose for interventional procedures.
  • The method investigates the use of XR-RV3 gafchromic films, punctual TLDs and TLD sheets to intercept the X-ray beam and measure the maximum skin dose.
  • RESULTS: XR-RV3 films, being large area dosemeters, proved to reproduce with good accuracy the dose distribution over the patient skin.
  • Nonetheless, significant dependence with beam energy and quality, reading and fitting process was observed, which introduces important uncertainties in maximum skin dose measurement.
  • Meanwhile, TLDs enabled precise dose estimates with lower uncertainty values but point TLD detectors may implicate missing the maximum dose location on the patient skin.
  • Thus, TLD sheets could represent the most adapted tool for the assessment of fluoroscopy-induced skin doses.
  • CONCLUSION: The developed protocol standardizes practices of patient skin dose estimates in interventional radiology.
  • Based on these results, the assessment, at European level, of alerts for interventional procedures using real-time Kerma-Area Product and Cumulative Air Kerma as skin dose indicators will be carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28519344.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Backscattering / Calibration / Data analysis / Dosimetry / Error analysis / Fluoroscopy / Medical physicists / Polynomials / Position sensitive detectors / Thermoluminescent dosimeters
  •  go-up   go-down


62. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Eur J Clin Pharmacol; 2017 May;73(5):581-591

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.
  • Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies.
  • No safety concerns or dose-limiting toxicities were identified (Study-1).
  • Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue.
  • CONCLUSIONS: Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 1976 Dec;58(6):676-82 [993482.001]
  • [Cites] Cell Death Dis. 2012 Jun 28;3:e334 [22739986.001]
  • [Cites] Am J Clin Dermatol. 2014 Oct;15(5):379-85 [25027461.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2203-13 [20081091.001]
  • [Cites] Curr Opin Pharmacol. 2015 Aug;23:82-91 [26093105.001]
  • [Cites] Int J Rheum Dis. 2014 May;17(4):359-68 [24460872.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):79-88 [18633443.001]
  • [Cites] Cell Signal. 2011 Apr;23(4):603-8 [20940048.001]
  • [Cites] J Autoimmun. 2011 May;36(3-4):278-87 [21396797.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2445-52 [17495954.001]
  • [Cites] Ann N Y Acad Sci. 2013 Mar;1280:24-6 [23551098.001]
  • [Cites] J Immunol. 2012 Nov 1;189(9):4612-20 [23024273.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1064-7 [18408745.001]
  • [Cites] Trends Immunol. 2007 Feb;28(2):80-7 [17208518.001]
  • [Cites] Open Rheumatol J. 2012;6:245-58 [23028409.001]
  • [Cites] Br J Dermatol. 2014 Jan;170(1):59-65 [24117368.001]
  • [Cites] J Invest Dermatol. 2014 Jan;134(1):268-71 [23812303.001]
  • [Cites] Arch Dermatol Res. 2011 Dec;303(10):691-705 [21863252.001]
  • [Cites] Rheumatology (Oxford). 2015 Feb;54(2):219-30 [25342375.001]
  • [Cites] Rheumatology (Oxford). 2012 Mar;51(3):552-6 [22120603.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2538-44 [18250464.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):496-509 [19641206.001]
  • [Cites] Front Immunol. 2012 Aug 23;3:256 [22936933.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2940-7 [17626838.001]
  • [Cites] J Autoimmun. 2015 Dec;65:1-18 [26515757.001]
  • (PMID = 28160012.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Inflammatory / PI3Kδ / Pharmacodynamic / Pharmacokinetic / Phase I / Seletalisib
  •  go-up   go-down


63. Barbero AM, Frederick Frasch H: Effect of stratum corneum heterogeneity, anisotropy, asymmetry and follicular pathway on transdermal penetration. J Control Release; 2017 Jun 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A quantitative and thorough study of skin permeation is essential for chemical exposure assessment and transdermal delivery of drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier B.V.
  • (PMID = 28596104.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Corneocyte / Diffusion / Lag time / Lipid bilayers / Partition coefficient / Skin appendages
  •  go-up   go-down


64. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC.
  • One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment.
  • The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups).
  • The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg).
  • Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Zhang K, Yassine M: Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol; 2009 May 20;27(15_suppl):4067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy (objective response, progression-free survival [PFS], and overall survival [OS]) and safety were evaluated by KRAS status.
  • RESULTS: In an interim analysis (May 2008) of 115 pts who had received ≥ 1 dose of pmab, 109 pts had known KRAS status (59% had tumors with wild-type [WT] KRAS, 41% had mutant [MT] KRAS tumors), and 102 pts had the opportunity to have their first tumor assessment.
  • Most common AEs were skin-related toxicities (86% of pts), diarrhea (72%), and nausea (53%); there was no evidence that incidence of AEs was related to KRAS status.
  • Pmab had a safety profile consistent with other FOLFIRI + pmab trials.
  • Final efficacy and safety data will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Dentan C, Forestier E, Roustit M, Boisset S, Chanoine S, Epaulard O, Pavese P: Assessment of linezolid prescriptions in three French hospitals. Eur J Clin Microbiol Infect Dis; 2017 Jan 26;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of linezolid prescriptions in three French hospitals.
  • Linezolid is approved in pneumonia and complicated skin and soft tissue infections.
  • Educational programs are mandatory to improve practices, as well as clinical studies to better assess the efficacy and safety of linezolid in clinical situations other than pneumonia or complicated skin and soft tissue infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28127641.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Narita K, Vo PTH, Yamamoto K, Kojima H, Itagaki H: Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays. Toxicol In Vitro; 2017 Aug;42:69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays.
  • In vitro safety tests may be used as replacements for animal tests owing to their accuracy and high-throughput performance.
  • However, several in vitro skin sensitization tests produce false-negative results such as acid anhydride.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28411127.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative / Drug exposure / False-negative / In vitro / Skin sensitization test / THP-1 cells
  •  go-up   go-down


68. Wang S, Mi J, Li Q, Jin R, Dong J: Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. Lasers Surg Med; 2017 Feb 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the various techniques, fractional microplasma radiofrequency technology (FMRT) has proven to be an effective treatment option for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation.
  • OBJECTIVE: This prospective clinical trial was designed to evaluate the efficacy and safety of FMRT for treating non-hypertrophic post-burn scars in the Asian population.
  • The Patient and Observer Scar Assessment Scales (POSAS) [20] were used to evaluate changes in burn scars pre-and post-FMRT treatment.
  • No severe adverse events, such as acute skin infection, hypertrophic scarring, or depigmentation, were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28220505.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; burns / cicatrix / lasers / micro-plasma / radiofrequency / scars
  •  go-up   go-down


69. Cheng CY, Huang YL, Lee MC, Chang SL, Lin YF, Hu S: Pulsed alexandrite laser for treatment of melasma in Asian patients. J Cosmet Laser Ther; 2017 Feb 02;:1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to evaluate the efficacy and safety of pulsed alexandrite laser for the treatment of melasma.
  • The severity of melasma was evaluated by a blinded dermatologist, using the Modified Melasma Area and Severity Index (MMASI), and by patient assessment, using a visual analogue scale, at baseline, before each treatment, and at the 1-month and 3-month follow-up visits after the last treatment.
  • The treatments were well tolerated with only mild skin reaction.
  • CONCLUSION: In the present study, we demonstrated that the pulsed alexandrite laser is safe and effective to treat melasma in Asian skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151024.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alexandrite laser / Asian / melasma
  •  go-up   go-down


70. Xiong J, Chiu Y, Pradhan RS, Li X, Li X, Carlson DM, Awni W: Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e13082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.
  • The aim of this assessment was to evaluate the impact of ethnicity on linifanib tolerability and pharmacokinetics (PK) in cancer patients.
  • The impact of ethnicity on tolerability was assessed by evaluating significance of ethnicity on the exposure-safety relationship.
  • Logistic regression analysis was conducted to construct the exposure-safety relationship for eight common adverse events (hypertension, asthenia, GI-abdominal disorder, diarrhea, skin toxicity 1, skin toxicity 2, proteinuria and anorexia).
  • RESULTS: The exposure-safety response analysis showed that ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Park KY, Kwon HJ, Lee C, Kim D, Yoon JJ, Kim MN, Kim BJ: Efficacy and safety of a new microneedle patch for skin brightening: A Randomized, split-face, single-blind study. J Cosmet Dermatol; 2017 Jun 02;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of a new microneedle patch for skin brightening: A Randomized, split-face, single-blind study.
  • BACKGROUND: Although microneedles are one of the best transdermal drug delivery systems for active compounds, few clinical trials have examined the safety and efficacy of brightening microneedle patches.
  • AIMS: To determine the efficacy and safety of a newly developed whitening microneedle patch.
  • PATIENTS/METHODS: A split-face study was designed for efficacy assessment with 34 Korean women applying the tested product (a whitening microneedle patch) on one cheek and a control whitening essence on the other.
  • We objectively measured changes in melanin index values and skin brightness by mexameter and chromameter.
  • Each participant also used global assessment to determine skin whitening.
  • In addition, 55 participants were selected for primary skin irritation tests and repeated insult patch tests for safety assessments.
  • RESULTS: Mean skin brightness and melanin indexes improved (P<.05) 4 weeks and 8 weeks after product use in both the whitening patch and whitening essence groups.
  • Global assessment by participants showed moderate cosmetic outcomes for both the whitening patch and whitening essence groups.
  • CONCLUSIONS: A newly developed microneedle patch was effective and safe for skin brightening and would be a promising functional cosmetic product.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28574158.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; clinical research / microneedle patch / skin brightening
  •  go-up   go-down


72. Jiang Y, Zhang X, Lu Z, Gold MH: Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity. J Cosmet Laser Ther; 2016 Dec 21;:1-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity.
  • : Skin aging, as a natural course, is a gradual process.
  • Fractional bipolar RF as a novel means of rejuvenation has been used in clinical practice, but questions remain in terms of its efficacy and safety.
  • Considering a large population in our country and huge demands for skin tightening, we did this research to evaluate the efficacy and safety of fractional bipolar radiofrequency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001455.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; MFWS / bipolar fractionated radiofrequency / skin laxity / wrinkle treatment
  •  go-up   go-down


73. Jones K, Johnson PD, Baldwin PEJ, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J: Exposure to Diisocyanates and Their Corresponding Diamines in Seven Different Workplaces. Ann Work Expo Health; 2017 Apr 01;61(3):383-393

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of this, any exposure to the diamines themselves released during the industrial process could confound the assessment of diisocyanate exposure.
  • This paper reports an initial assessment of the extent of diamine formation and exposure during different processes involving diisocyanates including casting, grouting, core making, spray painting, foam blowing, and floor screeding.
  • Some non-aerosol processes gave rise to substantial diamine levels in urine (in exceedance of international guidance values, >5 µmol mol-1 creatinine) despite airborne levels being well within occupational exposure limits (20 µg m-3 total NCO in Great Britain); measurement data and statistical modelling indicated that skin absorption was the most likely exposure route.
  • It also demonstrates the potential for substantial skin absorption of diisocyanates in certain processes such as floor screeding and foam production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Crown Copyright 2017.
  • (PMID = 28355438.001).
  • [ISSN] 2398-7316
  • [Journal-full-title] Annals of work exposures and health
  • [ISO-abbreviation] Ann Work Expo Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; NCO / diamines / diisocyanates / floor screeding / foam blowing / skin absorption
  •  go-up   go-down


74. Hojerová J, Peráčková Z, Beránková M: Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication. Food Chem Toxicol; 2017 May;103:66-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication.
  • Sunscreens are intended to work on the skin.
  • The potential for systemic absorption of Benzophenone-3 (BP3, 10%) and Ethylhexyl Triazone (EHT, 5%) in a silicone-based water-in-oil emulsion was assessed in vitro using a full-thickness porcine-ear skin mimicking in-use conditions.
  • (ii) on the whole-body skin, was (i) 136 and 30;.
  • Skin shaving increased BP3 and EHT bioavailability 1.38 and 1.80-fold, respectively.
  • Margin of Safety values were estimated according to guidelines applicable for European Union.
  • For three realistic exposure scenarios, MoS of 48, 34 and 34 for BP3 in the sunscreen applied on the whole-body indicate some concerns regarding the safety for consumers (MoS<100).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28216167.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Benzophenone-3 / Ethylhexyl triazone / Human exposure assessment / Margin of safety / Shaving skin / Systemic exposure dose
  •  go-up   go-down


75. Ford KA: Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods. ILAR J; 2016 Dec;57(2):226-233
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with the potential capacity to reduce or replace the use of animals for the assessment of particular toxicological endpoints, computational models offer several advantages compared to in vitro and in vivo approaches, including cost-effectiveness, rapid availability of results, and the ability to fully standardize procedures.
  • Models are currently available to aid in the prediction of several important toxicological endpoints, including mutagenicity, carcinogenicity, eye irritation, hepatotoxicity, and skin sensitization, albeit with varying degrees of success.
  • This review serves to introduce the concepts of computational toxicology and evaluate their role in the safety assessment of compounds, while also highlighting the application of in silico methods in the support of the goal and vision of the 3Rs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research.All rights reserved. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28053075.001).
  • [ISSN] 1930-6180
  • [Journal-full-title] ILAR journal
  • [ISO-abbreviation] ILAR J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3Rs / QSAR / alternative testing method / computational toxicology / drug development / in silico prediction
  •  go-up   go-down


76. Frederick DM, Vorwerk L, Gupta A, Ghassemi A: Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin. Cutan Ocul Toxicol; 2017 Jan 11;:1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin.
  • CONTEXT: The prevalence of sensitive skin among the general population in industrialized countries is reported to be over 50%.
  • Sensitive skin subjects often report significant reactions to contact with cosmetics, soaps and other consumer products.
  • OBJECTIVE: This paper describes the overall skin compatibility and mildness program for a newly developed, lightly fragranced, colorant free laundry product (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent), specially formulated for individuals with sensitive skin.
  • The skin mildness of the product was compared to Arm & Hammer™ Free & Clear liquid laundry detergent with no fragrance or colorant, and an established history of safe use by sensitive skin consumers.
  • MATERIALS AND METHODS: The test material was a liquid laundry product with a light scent formulated for sensitive skin consumers (Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent).
  • The product was compared to commercially marketed products for sensitive skin with a history of skin safety in the marketplace, including: a very similar product formulation (Arm & Hammer™ Free & Clear with no fragrance), and several selected competitors' products.
  • Studies were conducted among individuals with self-assessed sensitive skin (based on a questionnaire) using standard protocols for the Human Repeat Insult Patch Test (HRIPT), 10-Day Cumulative Irritation, the Wrist Band Wear test, and the Safety In-Use testing.
  • RESULTS: The HRIPT confirmed that neither the fragrance alone, nor the product formulation with fragrance, induced contact sensitization in sensitive skin subjects.
  • The 10-Day cumulative irritation study conducted using sensitive skin subjects showed highly favorable skin compatibility, and the test product was comparable to the control product (Arm & Hammer Free & Clear) and other nonirritant controls.
  • In the Wrist Band Wear test, exposure to laundered fabrics under exaggerated conditions gave similar results for the test and control products, with no objective signs of skin irritation, and no self-reported persistent adverse sensory effects.
  • The Safety In-Use tests evaluated 4-week exposure to product and laundered fabrics under realistic use conditions.
  • There were no clinically objective signs of skin irritation, and reports of transitory, mild sensory effects were minimal and similar for the test and controls.
  • DISCUSSION AND CONCLUSION: A comprehensive skin safety program on a lightly scented sensitive skin laundry formulation (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent) conducted among panels of self-assessed sensitive skin subjects demonstrated that the presence of a light fragrance did not adversely impact skin compatibility in any of the testing protocols when the product was compared to a similar product with no fragrance.
  • The lightly fragranced product demonstrated overall skin compatibility and mildness when tested in a self-assessed sensitive skin population, and compared favorably to currently marketed sensitive skin products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28073339.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Consumer product safety / contact sensitization / cumulative irritation / safety in use test / sensitive skin / skin irritation / wrist band test
  •  go-up   go-down


77. Abruzzo A, Armenise N, Bigucci F, Cerchiara T, Gösser MB, Samorì C, Galletti P, Tagliavini E, Brown DM, Johnston HJ, Fernandes TF, Luppi B: Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone. Int J Pharm; 2017 May 30;524(1-2):9-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone.
  • One of the most widely used approaches for improving drug permeation across the stratum corneum barrier of the skin is the use of chemical penetration enhancers, such as surfactants.
  • Assessment of impacts on HaCaT keratinocyte cell viability was used as indicator of their potential to cause skin irritation 24h post exposure (Alamar Blue assay).
  • The effect of different surfactant concentrations (up to ten times the critical micellar concentration, CMC) on hydrocortisone (HC) solubility and permeation through porcine skin was also evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356226.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cytotoxicity / Hydrocortisone / Keratinocyte / Micellar solubilization / Skin permeation enhancement / Surfactants
  •  go-up   go-down


78. Considine J, Hutchison AF, Rawson H, Hutchinson AM, Bucknall T, Dunning T, Botti M, Duke MM, Street M: Comparison of policies for recognising and responding to clinical deterioration across five Victorian health services. Aust Health Rev; 2017 May 25;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most health services' definitions of physiological observations fulfilled national standards in terms of minimum parameters and frequency of assessment.
  • </b> Recognising and responding to clinical deterioration is a major patient safety priority.
  • Although nurses are largely responsible for physiological observations and escalation of care, they have little authority to direct frequency of observations and triggers for care escalation or tailor assessment to individual patient needs.
  • </b> Inconsistencies in recommendations regarding physiological observations and escalation of care criteria may create patient safety issues when students and staff work across organisations or move from one organisation to another.
  • The validity of other parameters, such as appearance, pain, skin colour and cognition, warrant further consideration as early indicators of deterioration that may be used by nurses to identify clinical deterioration earlier.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28538140.001).
  • [ISSN] 0156-5788
  • [Journal-full-title] Australian health review : a publication of the Australian Hospital Association
  • [ISO-abbreviation] Aust Health Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Kendall R, Lenoir J, Gerrard S, Scheuerle RL, Slater NK, Tuleu C: Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System. Pharm Res; 2017 Feb 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.
  • However concerns exist around dermatological nipple tolerability with no pharmaceutical safety assessment guidance to study local tissue tolerance of the nipple and the areola.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28194635.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; nipple shield delivery system / pediatric / skin tolerability / slug mucosal irritation assay / tablet excipients
  •  go-up   go-down


80. Greveling K, Prens EP, Liu L, van Doorn MB: Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. J Eur Acad Dermatol Venereol; 2017 Jan 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures.
  • The quality of evidence was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
  • The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, and types of pain scales varied widely among the included studies.
  • In general, active non-invasive anaesthetic methods seemed to provide favourable results compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in a better pain reduction than skin cooling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107576.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


81. Waldmann V, Narayanan K, Combes N, Jost D, Jouven X, Marijon E: Electrical cardiac injuries: current concepts and management. Eur Heart J; 2017 Apr 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrical injuries can range from minor skin burns to life threatening internal organ damage.
  • A thorough clinical assessment to ascertain the path of current through the body and possible internal injury is essential.
  • Public education and increasing workplace as well as home safety measures are key steps in prevention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28444167.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrhythmias / Electric injuries / Lightning / Management / Physiopathology
  •  go-up   go-down


82. Al Jarallah M, Kassir R, El-Barbari M, Ali S, Debs T, Chouillard E: Three-Year Follow-Up of Laparoscopic Reduced Port Sleeve Gastrectomy in 808 Consecutive Patients. Obes Surg; 2017 May 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary and safety profile of <sub>R</sub>LSG as well as 3 years weight loss outcome are hereby discussed.
  • The <sub>R</sub>LSG procedure was performed using only two skin incisions.
  • Moreover, 3-year follow-up assessment confirmed adequate % EWL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28474321.001).
  • [ISSN] 1708-0428
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Gastrectomy / Laparoscopy / Obesity / Sleeve / Surgery
  •  go-up   go-down


83. Makino ET, Kadoya K, Sigler ML, Hino PD, Mehta RC: Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations. J Drugs Dermatol; 2016 Dec 01;15(12):1562-1570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
  • OBJECTIVES: To develop a comprehensive product (LYT2) that affects all major biological pathways controlling pigmentation and test for clinical efficacy and safety in different ethnic populations.
  • METHODS: A thorough analysis of biological pathways was used to identify ingredient combinations for LYT2 that provided optimal melanin reduction in a 3-D skin model.
  • The outcome clearly shows greater pigmentation control with LYT2 compared to other HQ-free products in skin tissue models and earlier control in clinical studies compared to 4% HQ.
  • [MeSH-major] Ethnic Groups. Hydroquinones / administration & dosage. Melanins / antagonists & inhibitors. Skin Lightening Preparations / administration & dosage. Skin Pigmentation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095579.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroquinones; 0 / Melanins; 0 / Skin Lightening Preparations; XV74C1N1AE / hydroquinone
  •  go-up   go-down


84. Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML: Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg; 2017 Jun;43(6):826-835
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment.
  • BACKGROUND: Platelet-rich plasma (PRP) is an emerging treatment in dermatology recently proposed for skin rejuvenation.
  • OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.
  • RESULTS: Clinical and patient evaluation showed improvement of skin texture.
  • Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved.
  • CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28375975.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Guo Y, Gu Z, Liu X, Liu J, Ma M, Chen B, Wang L: Rapid Analysis of Corni fructus Using Paper Spray-Mass Spectrometry. Phytochem Anal; 2017 Jul;28(4):344-350

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a number of counterfeits of Corni fructus, such as Crataegi fructus, Lycii fructus, and grape skin are illegally sold in crude herb markets.
  • Therefore, the development of a rapid and high-throughput quality evaluation method is important for ensuring the effectiveness and safety of the crude materials of Corni fructus.
  • OBJECTIVE: To develop PS-MS chemical profiles and a semi-quantitative method of Corni fructus for quality assessment and control, and species distinction of Corni fructus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 John Wiley & Sons, Ltd.
  • (PMID = 28239915.001).
  • [ISSN] 1099-1565
  • [Journal-full-title] Phytochemical analysis : PCA
  • [ISO-abbreviation] Phytochem Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Corni fructus / chemical profile / paper spray-mass spectrometry / rapid analysis / species distinction
  •  go-up   go-down


86. Vukmanović S, Sadrieh N: Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening. Crit Rev Toxicol; 2017 May;47(5):415-432

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.
  • The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326907.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Allergic contact dermatitis / HLA / T cells / cosmetics / delayed-type hypersensitivity / dendritic cells / fragrance / hapten / human-repeated insult patch test / keratinocytes / local lymph node assay / skin sensitization
  •  go-up   go-down


87. Gawdat HI, Tawdy AM, Hegazy RA, Zakaria MM, Allam RS: Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study. J Cosmet Dermatol; 2017 Apr 05;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study.
  • BACKGROUND: The escalating urge for a youthful-looking skin instigates continuous innovations with minimally invasive procedures.
  • OBJECTIVE: Compare the efficacy and safety of PRP to readymade growth factors in skin rejuvenation.
  • PATIENTS AND METHODS: Twenty adult females with Fitzpatrick skin types III-IV and Glogau photoaging types II and III were enrolled in this study.
  • RESULTS: Both procedures yielded significant improvement regarding both GAIS (skin turgor and overall vitality) and OCT (epidermal and dermal thickness) assessment.
  • CONCLUSION: Platelet-rich plasma is effective and safe for skin rejuvenation, comparable to readymade growth factors with noticeable higher longevity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382785.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; OCT / PRP / efficacy / readymade growth factors / skin rejuvenation
  •  go-up   go-down


88. Jankowska A, Czerczak S, Kupczewska-Dobecka M: [Assessment of predictive dermal exposure to chemicals in the work environment]. Med Pr; 2017 Jun 14;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of predictive dermal exposure to chemicals in the work environment].
  • Assessment of dermal exposure to chemicals in the work environment is problematic, mainly as a result of the lack of measurement data on occupational exposure to chemicals.
  • Due to common prevalence of occupational skin exposure and its health consequences it is necessary to look for efficient solutions allowing for reliable exposure assessment.
  • This paper presents examples of models to assist the employer in the the assessment of occupational exposure associated with the skin contact with chemicals, developed in European Union (EU) countries, as well as in countries outside the EU.
  • Based on the literature data dermal exposure models EASE (Estimation and Assessment of Substance Exposure), COSHH Essentials (Control of Substances Hazardous to Health Regulations), DREAM (Dermal Exposure Assessment Method), Stoffenmanager , ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment), MEASE (Metal's EASE), PHED (Pesticide Handlers Exposure Database), DERM (Dermal Exposure Ranking Method) and RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals) were briefly described.
  • Problem of full work shift dermal exposure assessment is described.
  • An example of exposure assessment using RISKOFDERM and effectiveness evaluation to date were also presented.
  • When no measurements are available, RISKOFDERM allows dermal exposure assessment and thus can improve the risk assessment quality and effectiveness of dermal risk management.
  • Na podstawie danych literaturowych w artykule krótko opisano wybrane modele do szacowania narażenia dermalnego: EASE (Estimation and Assessment of Substance Exposure – oszacowanie i ocena narażenia na substancję), COSHH Essentials (Control of Substances Hazardous to Health Regulations – utrzymywanie pod kontrolą substancji niebezpiecznych dla zdrowia), DREAM (Dermal Exposure Assessment Method – metoda oceny narażenia dermalnego), Stoffenmanager, ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment – ukierunkowane szacowanie ryzyka Europejskiego Centrum ds.
  • Ekotoksykologii i Toksykologii Chemikaliów), MEASE (Metal’s EASE), PHED (Pesticide Handlers Exposure Database – baza danych na temat narażenia użytkowników pestycydów), DERM (Dermal Exposure Ranking Method – metoda rankingu narażenia dermalnego) i RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals – ocena ryzyka wynikającego z narażenia dermalnego na chemikalia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license.
  • (PMID = 28638154.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; RISKOFDERM / dermal exposure / exposure assessment / occupational exposure / occupational hygiene / predictive models
  •  go-up   go-down


89. Sowada J, Lemoine L, Schön K, Hutzler C, Luch A, Tralau T: Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin. Arch Toxicol; 2017 Jun;91(6):2331-2341

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.
  • This study now shows that readily isolable skin commensals transform B[a]P into a range of highly cyto- and genotoxic metabolites that are excreted in toxicologically relevant concentrations during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005 Jul 11;33(12):3799-811 [16009812.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):492-7 [19414215.001]
  • [Cites] Arch Toxicol. 2016 Jun;90(6):1449-58 [26238291.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):113-25 [15660110.001]
  • [Cites] Atmos Environ. 1969 Sep;3(5):565-72 [4187590.001]
  • [Cites] Science. 2009 Dec 18;326(5960):1694-7 [19892944.001]
  • [Cites] Appl Microbiol Biotechnol. 2006 Jul;71(4):522-32 [16317545.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14 [15688365.001]
  • [Cites] EXS. 2009;99:151-79 [19157061.001]
  • [Cites] MBio. 2013 Oct 29;4(6):e00782-13 [24169577.001]
  • [Cites] Arch Toxicol. 2014 Dec;88(12):2135-90 [25370008.001]
  • [Cites] Environ Toxicol Chem. 2001 Mar;20(3):632-43 [11349866.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jun 27;223(2):177-83 [12829283.001]
  • [Cites] Methods Enzymol. 1990;188:148-53 [2280701.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):1-15 [19442441.001]
  • [Cites] Chem Res Toxicol. 2011 Oct 17;24(10 ):1653-67 [21916506.001]
  • [Cites] Environ Sci Pollut Res Int. 2015 Nov;22(21):16393-404 [25471715.001]
  • [Cites] FEMS Microbiol Ecol. 2014 Apr;88(1):129-39 [24372170.001]
  • [Cites] Crit Rev Microbiol. 2015;41(3):326-40 [24645635.001]
  • [Cites] Cell Mol Life Sci. 2015 Apr;72(8):1499-515 [25548803.001]
  • [Cites] Cell. 2016 May 5;165(4):801-11 [27153494.001]
  • [Cites] Science. 2009 May 29;324(5931):1190-2 [19478181.001]
  • [Cites] J Environ Monit. 2007 Sep;9(9):1001-8 [17726562.001]
  • [Cites] Toxicol Lett. 2013 Apr 12;218(2):97-104 [23391484.001]
  • [Cites] EXS. 2009;99:57-86 [19157058.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1847-53 [9806168.001]
  • [Cites] Environ Monit Assess. 2008 Apr;139(1-3):107-18 [17566864.001]
  • [Cites] Biomed Chromatogr. 2016 Mar;30(3):474-83 [26230188.001]
  • [Cites] PLoS One. 2016 Jan 15;11(1):e0147239 [26771904.001]
  • [Cites] Cell. 2012 Mar 16;148(6):1258-70 [22424233.001]
  • [Cites] Drug Metab Pharmacokinet. 2006 Aug;21(4):257-76 [16946553.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):411-25 [25476418.001]
  • [Cites] Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42 [7703357.001]
  • [Cites] FEMS Microbiol Rev. 2008 Nov;32(6):927-55 [18662317.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):908-15 [10706104.001]
  • [Cites] Mucosal Immunol. 2012 Sep;5(5):567-79 [22617837.001]
  • [Cites] Exp Dermatol. 2012 May;21(5):364-9 [22509834.001]
  • [Cites] Curr Opin Chem Biol. 2013 Jun;17(3):379-84 [23680493.001]
  • [Cites] Environ Mol Mutagen. 2016 Apr;57(3):229-35 [26919089.001]
  • [Cites] Biochemistry. 1977 Apr 5;16(7):1467-73 [191070.001]
  • [Cites] Toxicol Sci. 2013 Feb;131(2):351-9 [23148024.001]
  • (PMID = 28378121.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Benzo[a]pyrene / Cytotoxicity / Genotoxicity / Microbiome / PAHs / Polycyclic aromatic hydrocarbons / Toxification
  •  go-up   go-down


90. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics. Int J Toxicol; 2017 May/Jun;36(1_suppl):17S-56S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the product use, formulation, and safety data of 115 amino acid alkyl amides, which function as skin and hair conditioning agents and as surfactants-cleansing agents in personal care products.
  • Safety test data on dermal irritation and sensitization for the ingredients with the highest use concentrations, lauroyl lysine and sodium lauroyl glutamate, were reviewed and determined to adequately support the safe use of the ingredients in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28553738.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; amino acid alkyl amides / cosmetics / safety
  •  go-up   go-down


91. Lotz C, Schmid FF, Oechsle E, Monaghan MG, Walles H, Groeber-Becker F: Cross-linked Collagen Hydrogel Matrix Resisting Contraction To Facilitate Full-Thickness Skin Equivalents. ACS Appl Mater Interfaces; 2017 Jun 21;9(24):20417-20425

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-linked Collagen Hydrogel Matrix Resisting Contraction To Facilitate Full-Thickness Skin Equivalents.
  • Full-thickness skin equivalents are gathering increased interest as skin grafts for the treatment of large skin defects or chronic wounds or as nonanimal test platforms.
  • To overcome these pitfalls, we aimed to chemically cross-link the dermal layer of a full-thickness skin model composed of a collagen type I hydrogel.
  • Finally, full-thickness skin equivalents were generated by seeding human epidermal keratinocytes on the surface of the equivalents and culturing these equivalents at an air-liquid interface.
  • These results indicate that cross-linking of collagen with PEG-SG reduces contraction of collagen hydrogels and thus increases the applicability of these models as an additional tool for efficacy and safety assessment or a new generation of skin grafts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28557435.001).
  • [ISSN] 1944-8252
  • [Journal-full-title] ACS applied materials & interfaces
  • [ISO-abbreviation] ACS Appl Mater Interfaces
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; alternatives to animal testing / collagen / cross-linking / regenerative medicine / skin grafts / tissue engineering
  •  go-up   go-down


92. Kim M, Lim J, Bae JM, Park HJ: A Pilot Study of the Efficacy of the POLARGEN&lt;sup&gt;®&lt;/sup&gt; Ultrahigh-frequency Electric Field (40.68 MHz) Radiofrequency Device in the Treatment of Facial Contouring. J Cosmet Laser Ther; 2017 May 30;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Various radiofrequency (RF) devices are used to treat skin laxity and for face contouring, but few studies have examined ultrahigh-frequency (UHF) electric field (40.68 MHz) RF devices.
  • OBJECTIVE: To evaluate the efficacy and safety of a UHF electric field (40.68 MHz) RF device for skin tightening and face contouring.
  • Clinical improvement was evaluated with the patient satisfaction score using a six-point scale and an assessment of clinical photographs taken at every visit and 2 months after the RF treatment.
  • Skin biopsies were obtained from one patient before the first treatment and immediately after the last treatment.
  • CONCLUSIONS: The UHF electric field RF device was effective for skin tightening and facial contouring, without significant adverse reactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28557650.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ultrahigh-frequency electric field / contouring / lower face / radiofrequency
  •  go-up   go-down


93. Luton A, Hernandez J, Patterson CR, Nielsen-Farrell J, Thompson A, Kaiser JR: Preventing Pressure Injuries in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: An Interprofessional Quality Improvement Project. Adv Neonatal Care; 2017 Jan 30;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interventions centered on revision of current protocols, with efforts to optimize product selection, hardwire assessment practices, and refine documentation of patient care and outcomes.
  • IMPLICATIONS FOR PRACTICE: Recognizing the unique skin protection needs of special populations within the NICU, such as those undergoing TH, is crucial.
  • IMPLICATIONS FOR RESEARCH: A paucity of literature regarding the unique skin protection needs for babies undergoing TH exists.
  • Work should be done to better describe the influence of TH on skin integrity, with the goal of identifying population-specific protective measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28141600.001).
  • [ISSN] 1536-0911
  • [Journal-full-title] Advances in neonatal care : official journal of the National Association of Neonatal Nurses
  • [ISO-abbreviation] Adv Neonatal Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Few J, Gold M, Sadick N: Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With Multipolar Radiofrequency andVaripulseTechnology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks. J Drugs Dermatol; 2016 Nov 01;15(11):1354-1358

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With Multipolar Radiofrequency andVaripulseTechnology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks.
  • BACKGROUND: Increasing demand for non-invasive skin tightening and body contouring procedures has led to several technological in- novations in energy-based devices such as ultrasound, radiofrequency and cryolipolysis.
  • An emerging trend in the eld is to evaluate whether combination therapies for skin laxity/body contouring using energy-based devices can deliver superior clinical results and patient satisfaction.
  • As such, the objective of this prospective, internal-controlled, blind clinical study was to assess the safety and efficacy of cryolipolysis followed by multipolar radiofrequency with pulsed electromagnetic elds (PEMF) and adjustable pulsed suction for the treatment of skin laxity in the flanks.
  • Side effects were recorded at every visit and patient satisfaction was noted at the one week, three and six-month follow-up using a 5-scale subject satisfaction assessment questionnaire.
  • RESULTS: Analysis of the blinded investigator ratings demonstrated statistical significant enhanced skin laxity mean improvement of 1 grade on the GAI scale in subject treated with the combination treatment (cryolipolysis+RF/PEMF/suction) compared with the cryolipolysis treatment alone.
  • CONCLUSION: The results of this study show that the combination of multipolar RF with PEMF/suction following cryolipolysis is a safe, effective, and painless approach to enhance skin tightening following fat reduction procedures in the flanks.
  • [MeSH-major] Cosmetic Techniques. Cryotherapy / methods. Radio Waves / therapeutic use. Skin / radiation effects. Subcutaneous Fat / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095547.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Redley B, Raggatt M: Use of standard risk screening and assessment forms to prevent harm to older people in Australian hospitals: a mixed methods study. BMJ Qual Saf; 2017 Mar 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of standard risk screening and assessment forms to prevent harm to older people in Australian hospitals: a mixed methods study.
  • BACKGROUND: Standard risk screening and assessment forms are frequently used in strategies to prevent harm to older people in hospitals.
  • (1) cross-sectional audit of the standard risk screening and assessment forms used to assess older people at 11 health services in 2015;.
  • RESULTS: 152 standard assessment forms from 11 Victorian health services included over 3700 items with 17% duplicated across multiple forms.
  • Assessments of skin integrity and mobility loss (including falls) were consistently included in forms; however, nutrition, cognitive state, pain and medication risks were inconsistent; and continence, venous thromboembolism risk and hospital acquired infection from invasive devices were infrequent.
  • Qualitative analyses revealed five themes explaining issues associated with current use of assessment forms:.
  • (1) comprehensive assessment of preventable harms;.
  • CONCLUSIONS: Current use of standard risk screening and assessment forms is associated with a high burden and gaps in assessment of several common preventable harms that can increase risk to older people in hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • (PMID = 28289243.001).
  • [ISSN] 2044-5423
  • [Journal-full-title] BMJ quality & safety
  • [ISO-abbreviation] BMJ Qual Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Health services research / Healthcare quality improvement / Patient safety / Risk management
  •  go-up   go-down


96. Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Dean T, Burrows NP, Pollock I, Buckley HK, Williams HC, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Wake EV, Mitchell EJ, Brown SJ, Montgomery AA: Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess; 2017 Apr;21(16):1-260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families.
  • Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness.
  • Safety outcomes - number of skin infections and hospitalisations for AE.
  • Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28409557.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S: Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis; 2017 Mar;4(2):49-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The US Food and Drug Administration (USFDA) had approved telavancin in 2009 for the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including MRSA (<i>S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus</i> group, or <i>Enterococcus faecalis</i>).
  • Phase II Telavancin versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections due to Gram-Positive Bacteria (FAST 1 and FAST 2) and phase III [Assessment of Telavancin in Complicated Skin and Skin Structure Infections 1 (ATLAS 1 and ATLAS 2)] clinical trials have been conducted for evaluating telavancin's efficacy and safety in cSSSIs.
  • Phase III clinical trials have been carried out for evaluating telavancin's safety and efficacy in nosocomial pneumonia [Assessment of Telavancin for Treatment of Hospital acquired Pneumonia 1 and 2 (ATTAIN 1 and ATTAIN 2)].
  • A phase II randomized, double-blind, clinical trial has been carried out for evaluating telavancin's safety and efficacy in uncomplicated <i>S. aureus</i> bacteremia [Telavancin for Treatment of Uncomplicated <i>S. aureus</i> Bacteremia (ASSURE)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28634536.001).
  • [ISSN] 2049-9361
  • [Journal-full-title] Therapeutic advances in infectious disease
  • [ISO-abbreviation] Ther Adv Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; MRSA / Telavancin (TD-6424) / second-generation lipoglycopeptide resistant Gram-positive infections / semisynthetic
  •  go-up   go-down


98. Barak-Shinar D, Del Río R, Green LJ: Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream. J Clin Aesthet Dermatol; 2017 Apr;10(4):17-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Objective:</b> Seborrheic dermatitis is a common relapsing inflammatory skin condition occurring in approximately 3 to 5 percent of the general population.
  • The study's objective was to determine the safety and efficacy of a barrier-based, nonsteroidal cream incorporating herbal extracts as a treatment for facial seborrheic dermatitis.
  • <b>Design:</b> Interventional, open label, safety/efficacy study.
  • The target area was evaluated for Investigator Static Global Assessment, desquamation (scaling), induration (inflammation), and erythema (redness) as well as self-assessed pruritus.
  • <b>Conclusion:</b> The study showed that after six weeks of treatment, the face cream provided improvement in Investigator Static Global Assessment, pruritus, desquamation, induration, and erythema.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Mycol. 1998;36 Suppl 1:119-28 [9988500.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [16382685.001]
  • [Cites] J Invest Dermatol. 2008 Feb;128(2):345-51 [17671514.001]
  • [Cites] Drugs. 1988;36 Suppl 5:15-23 [3076129.001]
  • [Cites] Am J Clin Dermatol. 2004;5(6):417-22 [15663338.001]
  • [Cites] Int J Dermatol. 1998 Jun;37(6):410-5 [9646122.001]
  • [Cites] P T. 2010 Jun;35(6):348-52 [20592880.001]
  • [Cites] Am Fam Physician. 2006 Jul 1;74(1):125-30 [16848386.001]
  • [Cites] J Clin Aesthet Dermatol. 2013 Feb;6(2):44-9 [23441240.001]
  • [Cites] Drugs. 1998 May;55(5):645-74 [9585862.001]
  • [Cites] J Drugs Dermatol. 2007 Oct;6(10):1001-8 [17966177.001]
  • [Cites] Mycoses. 2012 Sep;55(5):393-403 [21966947.001]
  • [Cites] Biochem J. 2009 Jul 15;421(3):473-82 [19442240.001]
  • [Cites] Clin Dermatol. 2013 Jul-Aug;31(4):343-51 [23806151.001]
  • [Cites] Acta Dermatovenerol Croat. 2008;16(4):226-30 [19111149.001]
  • [Cites] Acta Pharm Sin B. 2015 Jul;5(4):310-5 [26579460.001]
  • [Cites] J Am Acad Dermatol. 2002 Dec;47(6):852-5 [12451368.001]
  • [Cites] Dermatology. 2003;207(4):375-80 [14657630.001]
  • [Cites] Phytother Res. 2000 May;14(3):210-2 [10815018.001]
  • [Cites] J Am Acad Dermatol. 2004 Nov;51(5):785-98 [15523360.001]
  • (PMID = 28458770.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Gold LS, Baldwin H, Rueda MJ, Kerrouche N, DrÉno B: Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females. J Clin Aesthet Dermatol; 2016 Jul;9(7):23-29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Objectives:</b> To evaluate the efficacy and safety of adapalene 0.1% benzoyl peroxide 2.5% gel in women aged 25 years or older via subgroup analysis of existing Phase 2 and 3 study data.
  • Efficacy assessments included investigator's global assessment and median percent change in acne lesions.
  • Safety assessments included skin tolerability and adverse events.
  • Comparison of the amount of difference between active and vehicle reductions in investigator's global assessment showed that efficacy was similar for adult females versus teen-aged females (20.7% vs. 19.9%, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Exp Med Biol. 1999;455:477-82 [10599385.001]
  • [Cites] Am J Clin Dermatol. 2006;7(5):281-90 [17007539.001]
  • [Cites] Cutis. 2007 Aug;80(2):152-7 [17944177.001]
  • [Cites] Cutis. 2009 Aug;84(2):110-6 [19746769.001]
  • [Cites] Dermatol Res Pract. 2010;2010:null [20706683.001]
  • [Cites] J Clin Aesthet Dermatol. 2015 Jan;8(1):31-7 [25610522.001]
  • [Cites] Skinmed. 2014 Jan-Feb;12(1):15-21 [24720080.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5):791-9 [17655969.001]
  • [Cites] Cutis. 2014 Oct;94(4):177-82 [25372252.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1063-70 [23302006.001]
  • [Cites] J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50 [19376456.001]
  • [Cites] Mini Rev Med Chem. 2014;14(8):629-41 [25141855.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1096-106 [25296739.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37 [12833004.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2012 Mar;26(3):277-82 [21848892.001]
  • [Cites] Cutis. 2003 Feb;71(2 Suppl):18-26 [12630671.001]
  • [Cites] Br J Dermatol. 2009 Nov;161(5):1180-9 [19466959.001]
  • [Cites] J Am Acad Dermatol. 1999 Oct;41(4):577-80 [10495379.001]
  • [Cites] J Clin Aesthet Dermatol. 2014 Feb;7(2):22-30 [24578779.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23 (5):529-32 [19192015.001]
  • [Cites] J Clin Aesthet Dermatol. 2013 Oct;6(10):32-5 [24155991.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):644-6 [16546586.001]
  • [Cites] Clin Interv Aging. 2006;1(4):327-48 [18046911.001]
  • [Cites] Int J Dermatol. 2014 Jan;53(1):114-22 [24168514.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Apr;29(4):789-96 [25399481.001]
  • (PMID = 28331557.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Lacour JP, Paul C, Jazayeri S, Papanastasiou P, Xu C, Nyirady J, Fox T, Papavassilis C: Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol; 2017 May;31(5):847-856

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection.
  • Efficacy responses [≥75/90/100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100) and clear/almost clear skin by Investigator's Global Assessment 2011 modified version (IGA mod 2011 0/1)] were measured at Week 52.
  • Patient-reported usability of the autoinjector was evaluated by the self-injection assessment questionnaire to Week 48.
  • CONCLUSION: Self-administration of secukinumab using an autoinjector was associated with robust and sustained efficacy, a good safety profile and high acceptability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28111801.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement